proline and telaprevir

proline has been researched along with telaprevir in 398 studies

Research

Studies (398)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (4.27)	29.6817
2010's	377 (94.72)	24.3611
2020's	4 (1.01)	2.80

Authors

Authors	Studies
Iino, S	1
Chen, HJ; Chovan, LE; Dandliker, PJ; Guan, Z; Hernandez, L; Kempf, DJ; Klein, C; Klein, LL; Lau, YY; Marsh, KC; Randolph, JT; Turner, TM; Yeung, C	1
Bes, M; Cubero, M; Esteban, JI; Esteban, R; Guardia, J; Otero, T; Quer, J; Sauleda, S	1
Bogen, S; Chase, R; Girijavallabhan, V; Guo, Z; Njoroge, FG; Prongay, A; Ralston, R; Saksena, A; Skelton, A; Tong, X; Xia, E	1
Kozal, MJ; Liu-Young, G	1
Pár, A; Pár, G	1
Gonzàlez-Candelas, F; López-Labrador, FX; Moya, A	1
López-Labrador, FX	1
Allen, TM; Berical, A; Berlin, AM; Bihl, F; Birch, C; Birren, BW; Carlson, J; Cerny, A; Chung, RT; Daar, ES; Donfield, SM; Edlin, BR; Fleckenstein, JF; Galagan, JE; Gomperts, ED; Heckerman, D; Henn, MR; Jacobson, IM; Kim, AY; Kleyman, M; Kodira, C; Koehrsen, M; Kuntzen, T; Lake-Bakaar, GV; Lauer, GM; Ledlie, T; Lee, B; Lennon, N; Liu, Z; Madey, MA; Marion, T; McMahon, CM; Nusbaum, C; Park, VM; Reyor, LL; Roberts, AD; Rosen, HR; Schneidewind, A; Schulze Zur Wiesch, J; Spengler, U; Talal, AH; Timm, J; Walker, BD; Xing, Y; Young, SK	1
Kronenberger, B; Zeuzem, S	3
Inoue, K; Watanabe, T; Yamada, M; Yoshiba, S	1
Cullen, C; Curry, S; Greene, J; Guo, Z; Liu, S; Qiu, P; Ralston, R; Sanfiorenzo, V; Skelton, A; Tong, X; Xia, E	1
Ciaramella, G; Corbau, R; Flores, MV; Strawbridge, J	1
Domingues, FS; Herrmann, E; Hughes, E; Karey, U; Ralston, R; Sarrazin, C; Susser, S; Tong, X; Wang, Y; Welsch, C; Zettler, M; Zeuzem, S	1
Nelson, DR	2
El-Duweik, J; Farnik, H; Geisslinger, G; Lötsch, J; Sarrazin, C; Schmidt, H; Welsch, C; Zeuzem, S	1
Back, D; Khoo, S; Seden, K	1
Deshpande, M; Huang, M; Miller, MD; Mo, H; Murray, B; Qi, X; Rhodes, G; Sun, SC; Wang, K; Wang, Y; Yang, C	1
Opar, A	1
Antinori, S; Milazzo, L	1
Rodríguez-Torres, M	2
Amad, M; Bethell, RC; Bolger, G; Cordingley, MG; Duan, J; Garneau, M; Kukolj, G; Lagacé, L; Llinàs-Brunet, M; Thibeault, D; White, PW	1
Bae, A; Chen, X; Harris, J; Ku, K; Miller, MD; Mo, H; Qi, X; Sun, SC; Wong, KA; Worth, A	1
Poordad, F	1
Lange, CM; Sarrazin, C; Zeuzem, S	1
Fried, MW	1
Asselah, T; Marcellin, P	2
Pawlotsky, JM	1
Halfon, P; Locarnini, S	1
Ciesek, S; Manns, MP	1
Pockros, PJ	1
Hofmann, WP; Zeuzem, S	2
Enserink, M	1
Imhof, I; Simmonds, P	1
Aronsohn, A; Jensen, D	1
Hunyady, B	1
Barreiro, P; Fernandez-Montero, JV; Labarga, P; Martin-Carbonero, L; Poveda, E; Soriano, V; Vispo, E	1
Gravitz, L	1
Schlütter, J	1
Rice, C	1
Traynor, K	2
Wood, NJ	1
Bukh, J; Ghanem, L; Gottwein, JM; Jensen, TB; Scheel, TK	1
Charlton, M	1
Alcorn, MC; Dieterich, DT; Rabkin, JG; Weiss, JJ	1
Sheridan, C	1
Cabrera, R; Draganov, PV; Limaye, AR	1
Corouge, M; Pol, S	2
Chung, TL; Herrmann, E; Hofmann, WP; Karey, U; Lötsch, J; Mihm, U; Osbahr, C; Sarrazin, C; Susser, S; Welsch, C; Zeuzem, S	1
Wapner, J	1
Manns, M	1
Back, D; Dieterich, D; Peters, M; Rockstroh, J; Sherman, KE; Soriano, V; Sulkowski, M	1
Ilyas, JA; Vierling, JM	2
Ciesek, S; Manns, MP; von Hahn, T	1
Jazwinski, AB; Muir, AJ	1
Dore, GJ; Matthews, GV; Rockstroh, J	1
Ghany, MG; Nelson, DR; Seeff, LB; Strader, DB; Thomas, DL	1
Bruno, R; Fagiuoli, S; Sacchi, P	1
Forestier, N; Füller, C; Grigorian, N; Perner, D; Sarrazin, C; Susser, S; Vermehren, J; Welker, MW; Zeuzem, S	1
Razonable, RR	1
Goossens, N; Negro, F	1
Stiefelhagen, P	1
Back, D; Seden, K	1
Rademacher, K; Schafer, JA; Tungol, A	1
Spooner, LM	1
Mutimer, DJ; Rowe, IA	1
Harrington, PR; Naeger, LK; Zeng, W	1
Battyáni, Z; Hunyady, B; Kovács, B	1
Muir, AJ	2
Carpio-Pedroza, JC; Cazares, F; Cruz-Rivera, MY; Escobar-Gutiérrez, A; Fonseca-Coronado, S; Rivera-Osorio, P; Ruíz-Pacheco, JA; Ruiz-Tovar, K; Vaughan, G; Vazquez-Pichardo, M	1
Buti, M; Homs, M	1
Iqbal, M; McCormick, PA	1
Williams, SC	1
Domingues, FS; Hartmann, C; Lemon, SM; Lengauer, T; Shimakami, T; Welsch, C; Yang, Y; Zeuzem, S	1
Ferenci, P; Reddy, KR	1
Butt, AA; Kanwal, F	1
Gambarin-Gelwan, M; Jacobson, IM	1
Bartlett, JG; Peters, MG; Pham, PA; Sherman, KE; Sulkowski, MS; Thomas, DL	1
Hézode, C	3
Kwo, PY	1
Forestier, N; Zeuzem, S	1
Bacon, BR; Khalid, O	1
Esteban, R; Shiffman, ML	1
Foster, GR; Serfaty, LD	1
Adhoute, X; Benali, S; Bourlière, M; Castellani, P; Khaloun, A; Oules, V; Portal, I; Wartelle-Bladou, C	1
Roche, B; Samuel, D	1
Sulkowski, MS	2
Mangia, A; Mottola, L	1
Kumar, CK; Sarin, SK	1
El Kassas, M; El Raziky, M; Esmat, G; Gamil, ME; Hassany, M	1
Fried, MW; McGowan, CE	1
Berg, T; Cornberg, M; Dollinger, M; Ferenci, P; Hinrichsen, H; Klinker, H; Kraus, M; Manns, M; Mauss, S; Peck-Radosavljevic, M; Sarrazin, C; Schmidt, H; Spengler, U; Wedemeyer, H; Wirth, S; Zeuzem, S	1
Barreiro, P; Labarga, P; Poveda, E; Soriano, V; Vispo, E	1
Fontaine, H; Pol, S	1
Reinke, T	1
Agarwal, K; Austin, A; Brown, A; Dillon, JF; Foster, GR; Fox, R; Fraser, A; Hayes, PC; Leen, C; Mills, PR; Mutimer, DJ; Ramachandran, P; Ryder, SD	1
Hézode, C; Pawlotsky, JM; Sarrazin, C; Zeuzem, S	1
Cheiab, B; Ioniţă-Radu, F; Raşcanu, A	1
Anderson, PL; Burton, JR; Everson, GT; Kiser, JJ	1
Crespo, G; Lens, S	1
Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E	1
Alkhouri, N; Zein, NN	1
Hong, BA; Kerr, T; North, CS	1
Afdhal, NH; Dusheiko, GM; Forns, X; Jacobson, IM; Jensen, DM; Pawlotsky, JM; Poordad, F; Schulz, J	1
Domínguez Muñoz, E; Fernández Castroagudín, J; Molina Pérez, E	1
Giordano, C	1
Francque, S; Ho, E; Michielsen, P	1
Fomsgaard, A; Gerstoft, J	1
Beard, MR; Locarnini, SA; Thompson, AJ	1
Bronte, F; Bruno, R; Cammà, C; Capursi, V; Cicchetti, A; Colombo, GL; Craxì, A; Di Marco, V; Enea, M; Gasbarrini, A; Petta, S	1
Casey, LC; Lee, WM	2
Saxena, V; Terrault, N	1
Cacoub, P; Picard, O	1
Jacobson, I; Jesudian, A; Welsch, C; Zeuzem, S	1
Ford, JA; Greanya, E; Partovi, N; Wilby, KJ; Yoshida, EM	1
Ingiliz, P; Rockstroh, JK	1
McHutchison, JG; Thompson, AJ	1
Erdmann, J	1
Chang, MF; Lim, J; Monto, A; Morgan, TR; Pocha, C; Ross, D; Yee, HS	1
Chevaliez, S; Pawlotsky, JM; Rodriguez, C	1
Barritt, AS; Fried, MW	1
Naggie, S; Sulkowski, MS	1
Thompson, AJ	1
Bruguera, M; Esteban, R; Forns, X; Planas, R; Quer, JC; Solà, R; Vergara, M	1
Amur, S; Pacanowski, M; Zineh, I	1
Perelson, AS; Ribeiro, RM; Rong, L	1
Pearlman, BL	1
Aghemo, A; Colombo, M; Degasperi, E	1
Dybowska, D; Halota, W; Kozielewicz, D	2
Fox, AN; Jacobson, IM	1
Fadda, V; Maratea, D; Messori, A; Trippoli, S	1
Assis, DN; Lim, JK	1
Burton, MJ; McGuire, BM; Passarella, MJ	1
Bourgeois, S; Colle, I; De Maeght, S; Deltenre, P; Delwaide, J; Francque, S; Laleman, W; Moreno, C; Mulkay, JP; Orlent, H; Reynaert, H; Stärkel, P	1
Bourlière, M; Bronowicki, JP; Delasalle, P; Leroy, V; Pageaux, GP; Pariente, A; Pol, S; Serfaty, L; Zoulim, F	1
Ali, A; Aydin, C; Cao, H; Deveau, LM; Huang, W; Newton, A; Ozen, A; Petropoulos, CJ; Romano, KP; Schiffer, CA; Silver, C; Soumana, D	1
Grammatikos, G; Vermehren, J; Zeuzem, S	1
Boesecke, C; Rockstroh, JK	1
Dusheiko, G; Wedemeyer, H	1
Bianic, F; Cure, S; Diels, J; Gavart, S; Jones, E	1
Ouzan, D	1
Chandy, GM; Conjeevaram, H; Jothimani, D	1
Pascale, A; Serfaty, L	1
Barry, M; Bergin, C; Kieran, J; Norris, S; O'Leary, A; Schmitz, S; Walsh, C	1
Flemming, JA; Terrault, NA	1
Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E	1
Deltenre, P; Moreno, C	1
Bárcena, R; Casado, JL; Del Campo, S; Dronda, F; Mateos, ML; Montes, M; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA	1
Barreiro, P; Benito, JM; Fernández-Montero, JV; Labarga, P; Poveda, E; Rallon, N; Sánchez, C; Soriano, V; Vispo, E	1
Asselah, T	2
Cooper, C; Druyts, E; El Khoury, AC; Lester, R; Mills, EJ; Thorlund, K; Yaya, S	1
Carlson, A; Gregorich, Z; Striker, R	1
Burton, JR; Everson, GT	1
de Knegt, RJ; Janssen, HL; Pan, Q; Peppelenbosch, MP	1
Barrantes-González, M; González-Colominas, E; Salas, E; Solà, R	1
Gellad, ZF; Muir, AJ; Reed, SD	1
Gane, E	1
Jacobson, IM; Marks, KM	1
Lemon, M	1
Boonstra, A; Janssen, HL; Spaan, M	1
Buti, M; Esteban, R	1
Sarrazin, C; Vermehren, J	1
Abu-Mouch, S; Baruch, Y; Ben-Ari, Z; Bruck, R; Kaspa, RT; Lurei, Y; Oren, R; Safadi, R; Shibolet, O; Shouval, D; Zuckerman, E	1
Aronsohn, A; Jensen, D; Muir, AJ; Swan, T	1
Harrington, PR; Lontok, E; Mani, N; Miller, V	1
Comee, MK; Malloy, M; Silva, M; Sitole, M; Spooner, L	1
Cornberg, M; Kirschner, J; Maasoumy, B; Manns, MP; Markova, AA; Mix, C; Port, K; Rogalska-Taranta, M; Serrano, BC; Sollik, L; Wedemeyer, H	1
Heil, EL; Hynicka, LM	1
Barnard, RJ; Chase, R; Curry, S; Frontera, MJ; Graham, DJ; Gupta, S; Howe, AY; Howe, JA; Hughes, E; Lahser, F; McMonagle, P; Silva, MO; Treitel, M	1
Fried, MW; Jensen, DM	1
Birnkrant, D; Carter, W; Chen, J; Fleischer, RD; Florian, J; Hammerstrom, TS; Jadhav, PR; Murray, J; Zeng, W	1
Nikitin, AV	1
Agnesod, D; Boglione, L; Cariti, G; D'Avolio, A; De Nicolò, A; Di Perri, G; Dilly Penchala, S; Mohamed Abdi, A; Simiele, M	1
Backus, LI; Belperio, PS; Cheung, RC; Hwang, EW; Mole, LA; Thomas, IC	1
Bota, S; Neghină, AM; Popescu, A; Şirli, R; Sporea, I; Străin, M	1
Cobb, B; Pockros, PJ; Vierling, JM; Vilchez, RA	1
Ahmed, F	1
de Jong, YP; Jacobson, IM; Jesudian, AB	1
Aguilera, V; Berenguer, M; Vinaixa, C	1
Apica, B; Chen, EY; Czul, F; Dubin, P; Lee, WM; Martin, P; Sclair, SN	1
Bazin-Karra, D; Blanc, F; Cacoub, P; Cazorla, C; Decaux, O; Karras, A; Lambotte, O; Longuet, M; Musset, L; Pialoux, G; Pol, S; Resche Rigon, M; Saadoun, D; Thibault, V; Vittecoq, D; Ziza, JM	1
Aouri, M; Buclin, T; Cavassini, M; Csajka, C; Decosterd, LA; Mercier, T; Moradpour, D; Rauch, A; Telenti, A	1
Aguilera, A; Barreiro, P; Benito, JM; Fernández-Montero, JV; Labarga, P; Maida, I; Rallón, NI; Rick, F; Sánchez-Parra, C; Soriano, V	1
Crespo, G; Forns, X; Londoño, MC	1
Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourlière, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Dao, T; de Ledinghen, V; Di Martino, V; Dorival, C; Feray, C; Fontaine, H; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Métivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Serfaty, L; Tran, A; Zarski, JP; Zoulim, F	1
Dolton, MJ; McLachlan, AJ; Ray, JE	1
Giguere, P; Sockalingam, S; Tseng, A; Wong, D	1
Aqel, BA; Charlton, MR; Henry, TM; Keaveny, AP; Koning, L; Murphy, JL; Pungpapong, S; Rosser, BG; Ryland, KL; Satyanarayana, R; Vargas, HE; Yataco, ML	1
Asch, SM; Chan, K; Clark, JA; Gifford, AL; Groessl, EJ; Hanchate, AD; Ho, SB; Lai, MN; Wong, JB	1
Alberti, A; Bruno, R; Cabibbo, G; Cammà, C; Capursi, V; Craxì, A; Enea, M; Gasbarrini, A; Petta, S; Ruggeri, M	1
Gunson, RN; Leitch, EC; McNaughton, AL; Templeton, K; Thomson, EC	1
Biesbroeck, LK; Falsey, RR; Moore, E; Scott, JD; Shinohara, MM; Taraska, C	1
Taylor, DR	1
Alshuth, U; Hueppe, D; Mauss, S	1
Corouge, M; Mallet, V; Pol, S; Sogni, P	1
Brown, J; Paladino, JA; Turner, SJ	1
Andonov, A; Kadkhoda, K; Kaita, K; Osiowy, C	1
Klinker, H; Mauss, S	1
Urbánek, P	1
Euliano, R; Juneja, M; Lewis, JH; Satoskar, R	1
Bublak, R	1
Blázquez-Pérez, A; Mar, J; San Miguel, R	1
Bianic, F; Cure, S; Curtis, S; Dusheiko, G; Gavart, S; Lee, S	1
Boucher, CA; Broekman, MM; Brouwer, JT; Burger, DM; de Knegt, RJ; Drenth, JP; Hoepelman, AI; Lamers, MH; Reesink, HW; van Hoek, B	1
Akiyama, MJ; Chan, SM; Hong, LK; Huddleston, L; Piotrowski, JI; Roytman, MM; Trujillo, R; Tsai, NC	1
Bañares, R; Fernández-Yunquera, A; Rincón, D; Salcedo, M	1
Serfaty, L	1
Back, D; Else, L	1
Agarwal, K; Barnabas, A	1
Chiari, E; Cocca, G; Moioli, MC; Morreale, M; Orso, M; Panzeri, C; Puoti, M; Rossotti, R; Travi, G	1
Colombo, M; D'Ambrosio, R	1
Aghemo, A; Bitetto, D; Bruno, R; Caraceni, P; Ciancio, A; Coco, B; Marzioni, M; Petta, S; Rendina, M; Valenti, L	1
Galle, PR; Grambihler, A; Kittner, JM; Koch, S; Schattenberg, JM; Schuchmann, M; Thieringer, F; Weinmann, A; Weiss, NM; Wiltink, J; Zimmermann, T	1
Calle Serrano, B; Cornberg, M; Maasoumy, B; Manns, MP; Markova, AA; Port, K; Sollik, L; Wedemeyer, H	1
Bichoupan, K; Dieterich, DT; Martel-Laferrière, V	1
Lim, TR; Mutimer, DJ; Tan, BH	1
Antinori, S; Cattaneo, D; Falvella, FS; Gervasoni, C; Magni, C; Milazzo, L; Peri, AM; Vidale, S	1
Liu, CJ	1
Backus, LI; Belperio, PS; Cheung, R; Mole, LA; Shahoumian, TA	1
Jiang, S; Lawson, KA; Park, C	1
Bukh, J; Gottwein, JM; Humes, D; Jensen, SB; Li, YP; Ramirez, S	1
Alberti, A; Colombo, M; Craxì, A; Rizzetto, M	1
Fontana, RJ; Tischer, S	1
Pol, S	1
Baka, M; Dyda, T; Opoka-Kegler, J; Stańczak, GP; Stańczak, JJ; Zabek, P	1
Fang, A; Heera, J; Kantaridis, C; Plotka, A; Vourvahis, M	1
Beste, LA; Green, PK; Ioannou, GN	2
Adhoute, X; Ansaldi, C; Bourlière, M; Castellani, P; Oules, V; Wendt, A	1
Boccaccio, V; Bruno, S	1
Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D	2
Dieterich, DT; Martel-Laferrière, V	1
Cybula, M; Szemraj, J	1
Geier, A	1
Gil-Gómez, I; Lorente-Fernández, L; Marrero-Álvarez, P; Monte-Boquet, E; Poveda-Andrés, JL	1
Calleja Hernández, MÁ; Fernández-López, C; García Collado, C; Jiménez Morales, A; López-Sepúlveda, R; Valencia Soto, C	1
Anwar, MI; Danielson, UH; Ehrenberg, AE; Gustafsson, SS; Schmuck, B; Stenberg, G	1
Booth, CL; Bridge, SH; Dusheiko, G; Garcia-Diaz, A; Haque, T; Irish, D; Jacobs, M; Labbett, W; Macartney, MJ; McCormick, AL; Rosenberg, W; Smith, C; Tanwar, S; Trembling, P; Velazquez, C	1
Gutierrez, JA; Wyles, DL	1
El-Serag, HB; Kanwal, F	1
Amiri, M; Bailly, F; Funingana, G; Gonçalves, F; Hartig-Lavie, K; Maynard, M; Pradat, P; Virlogeux, V; Zoulim, F	1
Chung, RT; deLemos, AS	1
Akberdin, IR; Clausznitzer, D; Demenkov, PS; Gursky, VV; Ivanisenko, NV; Ivanisenko, VA; Kaderali, L; Kolchanov, NA; Kozlov, KN; Likhoshvai, VA; Mishchenko, EL; Samsonov, AM; Samsonova, MG; Todorov, DI	1
Canva, V; Deltenre, P; Deuffic-Burban, S; Dhumeaux, D; Larrey, D; Mallet, V; Mathurin, P; Obach, D; Pageaux, GP; Pol, S; Roudot-Thoraval, F; Schwarzinger, M; Yazdanpanah, Y	1
Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N	1
Catalli, L; Chua, J; Manos, MM; Monto, A; Murphy, RC; Pauly, MP; Saxena, V; Shvachko, VA; Terrault, NA; Wayne, E; Yee, HS	1
Sogni, P	1
Backus, LI; Belperio, PS; Mole, LA; Shahoumian, TA	1
Bruno, R; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A	1
Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourliere, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Chazouilleres, O; Dao, T; De Ledinghen, V; Di Martino, V; Dorival, C; Fontaine, H; Fontanges, T; Gournay, J; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Metivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Portal, I; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Tran, A; Zarski, JP; Zoulim, F	1
Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M	1
Angelillo, IF; Coppola, N; Pisaturo, M; Sagnelli, C; Sagnelli, E	1
Gimeno-Ballester, V; Mar, J; San Miguel, R	1
Aichelburg, MC; Boesecke, C; Lang, G; Mandorfer, M; Niederecker, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R; Trauner, M	1
Brown, RS; Burton, JR; Dodge, JL; Everson, GT; Levitsky, J; O'Leary, JG; Saxena, V; Stravitz, RT; Terrault, NA; Trotter, JF; Verna, EC	2
Berg, T; Buggisch, P; Buslau, A; Hinrichsen, H; Maasoumy, B; Sarrazin, C; Schiefke, I; Wedemeyer, H; Wiegand, J	1
Abergel, A; Boyer, A; Lamblin, G; Sautou, V; Talavera Pons, S	1
Barth, H; Baumert, TF; Bukh, J; Doffoël, M; Fofana, I; Habersetzer, F; Heydmann, L; Patel, AH; Soulier, E; Xiao, F; Zeisel, MB	1
Borland, J; Chen, S; Johnson, M; Piscitelli, S; Savina, P; Wynne, B	1
Lawitz, EJ; Membreno, FE	1
Backus, LI; Belperio, PS; Mole, LA; Neuhauser, MM; Ross, D	1
Bichoupan, K; Dieterich, DT	1
Uetrecht, J; Weston, JK	1
Degen, O; Eißing, F; Hennigs, A; Hertling, S; Hüfner, A; Jordan, S; Lohse, AW; Lüth, S; Röder, C; Schmiedel, S; Schulze zur Wiesch, J; Sterneck, M; van Lunzen, J; Wehmeyer, MH	1
Chowdhury, AY; George, SL; Tavis, JE	1
Brown, RS; Dove, LM; Fox, AN; Lukose, T; Mentore, K; Olsen, SK; Shetty, K; Terry, N; Verna, EC	1
Bernstein, B; Chevaliez, S; Cloherty, G; Cohen, D; Herman, C; Pawlotsky, JM; Sarrazin, C; Wedemeyer, H	1
Thompson, JR	1
Agarwal, K; Barnabas, A; Orrin, E; Walsh, SA	1
Asselah, T; Boyer, N; Bronowicki, JP; Carrat, F; Dorival, C; Guedj, J; Hézode, C; Khelifa-Mouri, F; Lada, O; Laouénan, C; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Mentré, F; Nicot, F; Peytavin, G; Serfaty, L; Zoulim, F	1
Bachovchin, DA; Bachovchin, WW; DiMare, M; Golub, TR; Healey, SE; Kiritsy, CP; Koblan, LW; Lai, JH; Li, Y; Liu, Y; Munford, RS; Poplawski, SE; Sanford, DG; Shu, Y; Woznica, I; Wu, W; Zhao, P	1
Furusyo, N; Hayashi, J; Hiramine, S; Mitsumoto, F; Murata, M; Ogawa, E; Shimizu, M; Takayama, K; Toyoda, K; Ura, K	1
Carrier, P; Chambaraud, T; Debette-Gratien, M; Essig, M; Jacques, J; Loustaud-Ratti, V; Rousseau, A; Sautereau, D; Vong, C	1
Belli, LS; Ciaccio, A; Cortesi, PA; De Salvia, S; Lim, JK; Mantovani, LG; Okolicsanyi, S; Rota, M; Strazzabosco, M; Vinci, M	1
Aherfi, S; Borentain, P; Botta-Fridlund, D; Bregigeon, S; Brouqui, P; Colson, P; Dhiver, C; Gérolami, R; Mokhtari, S; Moreau, J; Motte, A; Poizot-Martin, I; Portal, I; Ravaux, I; Ruiz, JM; Solas, C; Stein, A; Tamalet, C	1
Ball, JK; Bartenschlager, R; Brown, RJ; Irving, WL; McClure, CP; Pietschmann, T; Rupp, D; Steinmann, E; Than, LM; Titman, A	1
Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z	1
Manos, MM; Murphy, RC; Pauly, MP; Price, JC; Shvachko, VA	1
Berdeaux, G; Bianic, F; Cure, S; de Knegt, RJ; Lamotte, M; van Agthoven, M; van der Kolk, A; Vellopoulou, A	1
Climente-Martí, M; Gómez-Álvarez, S; Guglieri-López, B; Ventura-Cerdá, JM	1
Andreone, P; Conti, F; Vitale, G	1
Fang, L; Hussaini, A; Kleha, JF; Theodore, D; Wire, MB	1
Backus, LI; Belperio, PS	1
Blanchard, E; Samaras, K; Vickers, CR	1
Alam, I; Argo, CK; Fried, MW; Gordon, SC; Lim, JK; Maliakkal, B; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Ramani, A; Reddy, KR; Stewart, TG; Vainorius, M	1
Zeuzem, S	1
Bruggmann, P; Fehr, J; Künzler-Heule, P; Nicca, D; Rasi, M; Saxer, S; Schmid, P; Semela, D	1
Bock, JA; Fairley, KJ; Inverso, NA; Maeng, DD; Pitcavage, JM; Smith, RE; Williams, MS	1
Chayama, K; Hayes, CN	1
Baroni, GS; Bertino, G; Brancaccio, G; Brindicci, G; Carretta, V; Cenderello, G; Ciancio, A; Cuccorese, G; Forte, P; Mangia, A; Marignani, M; Minerva, N; Mottola, L; Orlandini, A; Piazzolla, V; Picciotto, A; Pirisi, M; Ripoli, M; Zignego, AL; Zuin, M	1
Bory, F; Broquetas, T; Cabrero, B; Cañete, N; Carrión, JA; Coll, S; García-Retortillo, M; Giménez, MD; González-Colominas, E; Knobel, H; Pellicer, R; Retamero, A; Salas, E; Solà, R	1
Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D	1
Bremer, B; Calvaruso, V; Cloherty, G; Craxì, A; Haragh, A; Hunyady, B; Maasoumy, B; Makara, M; Manns, MP; Sarrazin, C; Susser, S; Vermehren, J; Wedemeyer, H	1
Firpi, RJ; Hilgenfeldt, E	1
Berg, T; Hamdi, N; Herrmann, E; Lange, C; Müller, T; Perner, D; Sarrazin, C; Susser, S; Zeuzem, S	1
Brochot, E; Capron, D; Castelain, S; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E	1
Asch, SM; Barnett, PG; Dally, SK; Gidwani, R; Goldhaber-Fiebert, JD; Lo, J; Owens, DK	1
Fangman, JJ; Guilfoyle, SM; Hyland, HA; Stockman, LJ; Vergeront, JM; Westergaard, RP	1
Dultz, G; Welzel, TM; Zeuzem, S	1
Butt, AA; Freiberg, MS; Justice, AC; Lo Re, V; Shaikh, OS; Sherman, KE; Yan, P	1
Bennis, Y; Bodeau, S; Brochot, E; Capron, D; Duverlie, G; Nguyen-Khac, E; Solas, C	1
Andreoni, M; Angelico, M; Antonucci, FP; Aragri, M; Babudieri, S; Ceccherini-Silberstein, F; Cento, V; De Leonardis, F; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gasbarrini, A; Landonio, S; Lenci, I; Magni, CF; Mancon, A; Manunta, A; Micheli, V; Mura, MS; Nicolini, LA; Nosotti, L; Parruti, G; Pellicelli, A; Perno, CF; Rizzardini, G; Sarrecchia, C; Siciliano, M; Taliani, G; Tontodonati, M; Vecchiet, J	1
Abel, L; Albert, ML; Barthe, Y; Bronowicki, JP; Carrat, F; Casrouge, A; Dorival, C; Fontaine, H; Fontanet, A; Gayat, E; Hézode, C; Lagaye, S; Mallet, V; Mottez, E; Pol, S; Sultanik, P; Theodorou, I	1
Abraham, GM; Akushevich, L; Di Bisceglie, AM; El-Genaidi, H; Fenkel, JM; Fried, MW; Kuo, A; Mah'moud, MA; Nelson, DR; Rustgi, VK; Sterling, RK; Stewart, PW; Stewart, TG; Sulkowski, MS	1
Alric, L; Bailly, F; Bourlière, M; Bronowicki, JP; Carrat, F; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Loustaud-Ratti, V; Métivier, S; Pradat, P; Samuel, D; Serfaty, L; Virlogeux, V; Zarski, JP; Zoulim, F	1
Arends, JE; Dabis, F; Fontaine, H; Gilbert, C; Lacombe, K; Loko, MA; Miailhes, P; Puoti, M; Rockstroh, JK; Rosenthal, E; Salmon, D; Sogni, P; Winnock, M; Wittkop, L	1
Gerlei, Z; Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Rókusz, L; Szalay, F; Telegdy, L; Tornai, I; Werling, K	1
Abdelrahman, T; Aitken, C; Gunson, RN; MacLean, AR; Shepherd, SJ; Thomson, EC	1
Behrer, CR; Kalsekar, A; Le, TK; Macaulay, D; Sorg, RA; Wei, J; Wu, EQ; Yuan, Y	1
Akiyama, MJ; Cheung, R; Ha, NB; Li, J; Nguyen, MH; Piotrowski, JI; Roytman, MM; Tsai, N; Vo, KP; Vu, VD; Vutien, P; Wantuck, J	1
Akker, Dv; Berry, SM; Broglio, KR; Daar, ES; Detry, MA; Kalsekar, A; Le, T; Lewis, RJ; Quintana, M; Spellberg, B; Yuan, Y	1
Beck, R; Berg, CP; Egetemeyr, DP; Franz, C; Lauer, UM; Malek, NP; Werner, CR	1
Feld, JJ; Sharma, SA	1
Albillos, A; Hernández-Guerra, M; Luis Calleja, J; Molina, E; Planas, R; Romero-Gómez, M; Turnes, J	1
Bhagani, S; Collado, A; de Los Santos-Gil, I; Delgado, M; Fehr, J; Haberl, A; López-Cortés, LF; Lutz, T; Mandorfer, M; Márquez, M; Mauss, S; Munteanu, DI; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S; Stoeckle, M	1
Abravanel, F; Alain, S; André-Garnier, E; Baazia, Y; Besse, B; Bouvet, D; Bouvier-Alias, M; Brochot, E; Caporossi, A; David-Tchouda, S; Duverlie, G; Fleury, H; Gaudy-Graffin, C; Gouriou, S; Gozlan, J; Guivarch, M; Haïm-Boukobza, S; Halfon, P; Hantz, S; Henquell, C; Lada, O; Lagathu, G; Larrat, S; LeGuillou-Guillemette, H; Mackiewicz, V; Margier, J; Maylin, S; Mirand, A; Mohamed, S; Morand, P; Mourez, T; Pawlotsky, JM; Pivert, A; Plantier, JC; Pronier, C; Ramière, C; Roque-Afonso, AM; Scholtes, C; Schvoerer, E; Thibault, V; Trimoulet, P; Vallet, S; Velay, A	1
Ho, S; Mehnert, A; Pacou, M; Pettré, S; Pisini, M; Taieb, V; Ustianowski, A; Van Sanden, S	1
Afdhal, NH; Rourke, M; Sethi, N; Sethi, S; Tapper, EB; Vong, A	1
Tornai, I	1
Ampuero, J; Andrade, RJ; Buti, M; Cabezas, J; Calleja, JL; Crespo, J; Del Campo, JA; Fernández, I; Forns, X; Lens, S; Millán, R; Rojas, L; Romero-Gómez, M	1
Alberti, A; De Franceschi, L; Dissegna, D; Donato, F; Fattovich, G; Ieluzzi, D; Iolascon, A; Lupo, F; Matté, A; Piovesan, S; Raffetti, E; Russo, R; Siciliano, A; Toniutto, P; Turrini, F; Zuliani, V	1
Kalsekar, A; Le, TK; Macaulay, D; Sorg, RA; Wei, J; Wu, EQ; Yuan, Y	1
Ianna, EA; Jones, TL; Reeves, GE; Tran, HA	1
Arain, A; Bastens, B; Bourgeois, S; Bruckers, L; Buntinx, F; d'Heygere, F; de Galocsy, C; Deltenre, P; Francque, S; George, C; Henrion, J; Janssens, F; Laleman, W; Mathei, C; Moreno, C; Nevens, F; Robaeys, G; Van Overbeke, L; Van Vlierberghe, H; Verrando, R	1
Ambrosioni, J; Aouri, M; Böni, J; Cavassini, M; Decosterd, L; Fehr, J; Furrer, H; Günthard, HF; Haubitz, S; Kovari, H; Ledergerber, B; Metzner, KJ; Rauch, A; Schaerer, V; Schmid, P; Stoeckle, M	1
Fraenkel, L; Garcia-Tsao, G; Lim, J; Monto, A; Reyna, V	1
Alshuth, U; Böker, K; Buggisch, P; Christensen, S; Hofmann, WP; Hüppe, D; Mauss, S; Pfeiffer-Vornkahl, H; Schott, E	1
Allam, S; Boursier, J; Bronowicki, JP; Canva, V; De Lédinghen, V; Ducancelle, A; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Moal, V; Poynard, T; Veillon, P; Vergniol, J; Zoulim, F	1
Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H	1
Abdi, AM; Allegra, S; Baiett, L; Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G	1
Arends, JE; Brinkman, K; Hoepelman, AI; Kortmann, W; Posthouwer, D; Reiss, P; Richter, C; Schinkel, J; Smit, C; van Assen, S; van der Ende, M; van der Meer, JT; van der Valk, M	1
Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M	1
Cockerham-Colas, L; Heo, M; Litwin, AH; Reynoso, S; Roose, RJ; Soloway, IJ; Tenore, C	1
Burger, DM; Buti, M; de Kanter, CT; DeMasi, R; Dofferhoff, AS; Drenth, JP; Ouwerkerk-Mahadevan, S; Witek, J; Zeuzem, S	1
Agostini, H; Alric, L; Antonini, TM; Botta-Fridlund, D; Calmus, Y; Coilly, A; De Ledinghen, V; Debette-Gratien, M; Duclos-Vallée, JC; Dumortier, J; Durand, F; Duvoux, C; Giostra, E; Guillaud, O; Latournerie, M; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Roche, B; Samuel, D; Saouli, AC	1
Babudieri, S; Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Falasca, K; Maggi, P; Magni, C; Martinelli, C; Menzaghi, B; Nicolini, LA; Parruti, G; Quirino, T; Ricci, E; Salomoni, E; Vichi, F	1
Baldanti, F; Barbarini, G; Bruno, R; Fiorina, L; Gulminetti, R; Landini, V; Mariani, B; Maserati, R; Novati, S; Paolucci, S	1
Bam, RA; Birkus, G; Cihlar, T; Frey, CR; Stray, KM; Tsai, L; Willkom, M; Yant, SR	1
Dybowska, D; Karwowska, K; Kozielewicz, D; Wietlicka-Piszcz, M	1
Bani-Sadr, F; Dabis, F; Gilbert, C; Loko, MA; Morlat, P; Neau, D; Rosenthal, E; Salmon, D; Simon, A; Valantin, MA; Wittkop, L	1
Abel, L; About, F; Albert, ML; Bronowicki, JP; Cagnot, C; Carrat, F; Cobat, A; Duffy, D; Fontaine, H; Hézode, C; Larrey, D; Marcellin, P; Niay, J; Oudot-Mellakh, T; Pedergnana, V; Pol, S; Rabiéga, P; Sultanik, P; Theodorou, I; Zoulim, F	1
Adeyi, O; Chen, L; Cotler, SJ; Deneke, MG; Duarte-Rojo, A; Feld, JJ; Fischer, SE; Malespin, M; McGilvray, ID; Selzner, N; Zita, D	1
Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H	1
Arends, JE; Burger, DM; Friederich, P; Koek, GH; Lieveld, FI; Siersema, PD; van Erpecum, KJ; van Meer, S; van Nieuwkerk, KM; van Vlerken, LG	1
Horn, M; Horvath, A; Jurse, P; Leber, B; Lemesch, S; Posch, A; Schmerböck, B; Spindelboeck, W; Stadlbauer, V; Stauber, RE; Stiegler, P; Streit, A; Tawdrous, M; Wuensch, G; Zettel, G	1
Han, P; Lei, Y; Lu, X; Qiao, Q; Xu, Z; Yang, J; Yao, M; Yin, W; Zhao, H	1
Benali, S; Bourliere, M; Camus, C; Castellani, P; Chiche, L; Gonzalez, D; Halfon, P; Khiri, H; Mohamed, S; Olive, D; Oules, V; Penaranda, G; Sayada, C	1
Alshuth, U; Buggisch, P; Galle, PR; Grimm, D; Hueppe, D; Mauss, S; Pfeiffer-Vornkahl, H; Zimmermann, T	1
Batskikh, SN; Chulanov, VP; Karandashova, IV; Neverov, AD	1
Barrail-Tran, A; Bellissant, E; Bourlière, M; Cotte, L; Fournier, I; Garraffo, R; Kheloufi, F; Lacarelle, B; Molina, JM; Poizot-Martin, I; Quaranta, S; Renault, A; Solas, C	1
Bartenschlager, R; Beggel, B; Heger, E; Kaiser, R; Kalaghatgi, P; Knops, E; Lengauer, T; Neumann-Fraune, M; Obermeier, M; Rupp, D; Sierra, S; Sikorski, AM; Timm, J; Walker, A; Walter, H	1
Goncales, ES; Goncales, FL; Lazarini, MS; Mendes, LC; Miotto, N; Pedro, MN; Stucchi, RS; Vigani, AG; Zanaga, LP	1
Akhan, S; Ayaz, C; Aygen, B; Aynioglu, A; Demirturk, N; Ersoz, G; Inan, D; Karakecili, F; Keten, D; Koculu, S; Korkmaz, F; Kose, Ş; Mistik, R; Sargin Altunok, E; Sayan, M; Tekin Koruk, S; Tuna, N; Ural, O; Yazici, S; Yildirmak, T; Yildiz, O	1
Abu Freha, N; Ben Yakov, G; Dizingof, V; Etzion, O; Fich, A; Monitin, S; Montano, D; Mushkalo, A; Shwarts, D; Sikuler, E; Takchick, A; Zilberman, D	1
Barreca, GS; Cuypers, L; Dierckx, T; Focà, A; Liberto, MC; Malanga, D; Marascio, N; Mirante, T; Oliveira, DM; Pavia, G; Strazzulla, A; Torti, C; Vandamme, AM; Vrancken, B	1
Carr, M; De Gascun, CF; Gray, E; Nguyen, LT; O'Leary, A	1
Anthony, DD; Bonomo, RA; Chandar, AK; Compan, A; Davitkov, P; Falck-Ytter, Y; Gideon, C; Hirsch, A; Silveira, MG; Smith, S	1
Friedel, H; Fröhlich, H; Thönnes, S	1
Yu, ML	1
Alvarez, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Islam, N; Janjua, NZ; Krajden, M; Ramji, A; Samji, H; Tyndall, M; Wong, J; Yoshida, EM	1
Bourlière, M; Carrat, F; Carrieri, MP; Fontaine, H; Hézode, C; Marcellin, F; Petrov-Sanchez, V; Protopopescu, C; Vilotitch, A; Younossi, Z	1
Gray, E; Norris, S; O'Leary, A; Pasta, DJ	1
Al Marzooqi, SH; Cerocchi, O; Duarte-Rojo, A; Feld, JJ; Harrell, SM; Janssen, HLA; Karkada, J; Klair, JS; Kowgier, M; Maan, R; Rhodes, KD	1
Ceccherini-Silberstein, F; Cento, V; Cuypers, L; Di Maio, VC; Libin, P; Lunar, MM; Nevens, F; Nowé, A; Poljak, M; Schrooten, Y; Theys, K; Van Laethem, K; Vandamme, AM	1
Álvares-Da-Silva, MR; Brandão-Mello, CE; Callefi, LA; Carnaúba-Júnior, D; Chachá, SGF; Coelho, HSM; de Barros Tenore, S; de Lourdes Candolo Martinelli, A; de Macedo Bisio, AP; de Mello Perez, R; de Souza Paiva Ferreira, A; Ferraz, MLCG; Ferreira, PRA; Ivantes, CAP; Mendes-Correa, MCJ; Nabuco, LC; Pessoa, MG; Pinto, PTA; Reuter, T; Villela-Nogueira, CA	1
Dammermann, W; Dettmann, I; Komorowski, L; Lüth, S; Mindorf, S; Polywka, S; Schulze Zur Wiesch, J; Stöcker, W; Wehmeyer, M	1
Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG	1
Chen, C; Hartigan-O'Connor, DJ; Khalili, M; Lanier, LL; Lu, D; Manos, MM; McCune, JM; Méndez-Lagares, G; Monto, A; Ryan, JC; Segal, MR; Shen, H; Terrault, N	1
Kjellin, M; Lannergård, A; Lennerstrand, J; Löfblad, E; Wesslén, T	1
Blatt, CR; Carneiro, JMM; Chachá, SGF; Farias, MR; Feltrin, AA; Gomes, LO; Martinelli, ALC; Noblat, LACB; Pereira, LRL; Rodrigues, JPV; Rosa, JAD; Silveira, MPT; Teixeira, MR; Vecchi, MD	1
Borba, HHL; Ferreira, VL; Minowa, E; Pontarolo, R; Rochau, U; Siebert, U; Sroczynski, G; Wiens, A	1
Cazarim, MS; Chachá, SGF; Martinelli, ALC; Pereira, LRL; Rodrigues, JPV	1
Bani-Sadr, F; Bourlière, M; Carrat, F; Chalouni, M; de Ledinghen, V; Dorival, C; Esterle, L; Fontaine, H; Lacombe, K; Larrey, D; Marc-Lacombe, J; Pol, S; Salmon, D; Sogni, P; Wittkop, L; Zucman, D	1
Chen, P; Duan, ZL; Hu, Y; Huang, C; Lei, J; Li, L; Li, MH; Li, WM; Li, WP; Li, YS; Lin, GF; Liu, FL; Liu, JM; Liu, X; Liu, Y; Long, YH; Lu, GW; Luo, RH; Mao, X; Ni, X; Qiao, J; Qu, W; Quan, B; Shen, C; Sun, W; Wang, K; Wang, YF; Wei, YQ; Xu, L; Yang, RC; Yang, S; Yang, W; Yang, X; Yao, R; You, J; Zeng, R; Zhang, HL; Zhang, J; Zheng, YT; Zhou, Y; Zou, J; Zou, QC	1
Padhi, AK; Tripathi, T	1

Reviews

147 review(s) available for proline and telaprevir

Article	Year
[Drugs for hepatitis B and C infection]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Feb-28, Volume: 65 Suppl 2 Pt. 1 Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Lamivudine; Mutation; Oligopeptides; Organophosphonates; Proline; Ribavirin; Serine Proteinase Inhibitors	2007
Hepatitis C protease and polymerase inhibitors in development. AIDS patient care and STDs, 2008, Volume: 22, Issue:6 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Multicenter Studies as Topic; Oligopeptides; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Randomized Controlled Trials as Topic	2008
Hepatitis C Virus NS3/4A Protease Inhibitors. Recent patents on anti-infective drug discovery, 2008, Volume: 3, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Oligopeptides; Proline; Viral Nonstructural Proteins	2008
Future treatment options for HCV: double, triple, what is the optimal combination? Best practice & research. Clinical gastroenterology, 2008, Volume: 22, Issue:6 Topics: Antiviral Agents; Cytidine; DNA-Directed RNA Polymerases; Drug Delivery Systems; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Oligopeptides; Polyethylene Glycols; Prodrugs; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin	2008
[Novel treatment for chronic hepatitis C in near future]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:4 Topics: Drug Delivery Systems; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors	2009
[Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications]. Pharmazie in unserer Zeit, 2011, Volume: 40, Issue:1 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins; Virus Replication	2011
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2011
New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Signal Transduction; Standard of Care; Virus Replication	2011
Hepatitis C virus resistance to protease inhibitors. Journal of hepatology, 2011, Volume: 55, Issue:1 Topics: Antiviral Agents; Drug Resistance, Viral; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Liver; Models, Molecular; Mutation; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins; Virus Replication	2011
Hepatitis in 2010: the dawn of a new era in HCV therapy. Nature reviews. Gastroenterology & hepatology, 2011, Volume: 8, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2011
A new standard of care for the treatment of chronic HCV infection. Nature reviews. Gastroenterology & hepatology, 2011, Volume: 8, Issue:5 Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Oligopeptides; Pharmacogenetics; Proline; Standard of Care; Treatment Outcome; United States	2011
[New therapeutic options in chronic hepatitis C virus infection]. Orvosi hetilap, 2011, May-29, Volume: 152, Issue:22 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2011
Directly acting antivirals against hepatitis C virus. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:8 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Discovery; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline	2011
New treatments for chronic hepatitis C virus infection. Medecine et maladies infectieuses, 2011, Volume: 41, Issue:11 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Serine Proteinase Inhibitors; Therapies, Investigational	2011
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS (London, England), 2011, Nov-28, Volume: 25, Issue:18 Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2011
An overview of emerging therapies for the treatment of chronic hepatitis C. Clinics in liver disease, 2011, Volume: 15, Issue:3 Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2011
Second-wave protease inhibitors: choosing an heir. Clinics in liver disease, 2011, Volume: 15, Issue:3 Topics: Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Simeprevir; Sulfonamides; Thiazoles; Viral Nonstructural Proteins	2011
Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterology clinics of North America, 2011, Volume: 40, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Nucleosides; Oligopeptides; Proline; Serine Proteinase Inhibitors; Viral Nonstructural Proteins	2011
Future of hepatitis C therapy: development of direct-acting antivirals. Current opinion in HIV and AIDS, 2011, Volume: 6, Issue:6 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Oligopeptides; Proline; Protease Inhibitors; Treatment Outcome	2011
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clinic proceedings, 2011, Volume: 86, Issue:10 Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir	2011
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Current opinion in HIV and AIDS, 2011, Volume: 6, Issue:6 Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Oligopeptides; Proline; Protease Inhibitors	2011
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. Journal of managed care pharmacy : JMCP, 2011, Volume: 17, Issue:9 Topics: Adolescent; Adult; Aged; Algorithms; Clinical Trials, Phase III as Topic; Drug Costs; Female; Hepatitis C, Chronic; Humans; Male; Managed Care Programs; Middle Aged; Oligopeptides; Patient Compliance; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; RNA, Viral; Viral Load; Young Adult	2011
Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ (Clinical research ed.), 2011, Nov-10, Volume: 343 Topics: Cost-Benefit Analysis; Drug Interactions; Drug Monitoring; Genotype; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic	2011
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. Orvosi hetilap, 2011, Dec-11, Volume: 152, Issue:50 Topics: Affect; Anemia, Hypochromic; Antiviral Agents; Autoimmune Diseases; Autoimmunity; Cardiovascular System; Clinical Trials as Topic; Drug Eruptions; Drug Synergism; Drug Therapy, Combination; Endocrine System Diseases; Eye; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Respiratory System; Ribavirin; Risk Factors; Thrombocytopenia	2011
Telaprevir for the treatment of chronic hepatitis C infection. Expert review of anti-infective therapy, 2011, Volume: 9, Issue:12 Topics: Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins	2011
[New agents for the treatment of hepatitis C]. Enfermedades infecciosas y microbiologia clinica, 2012, Volume: 30, Issue:3 Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Discovery; Drug Eruptions; Drugs, Investigational; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain; Viral Nonstructural Proteins	2012
Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Antiviral therapy, 2011, Volume: 16, Issue:8 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load	2011
Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-01, Volume: 54, Issue:1 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2012
Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. Current gastroenterology reports, 2012, Volume: 14, Issue:1 Topics: Drug Resistance, Viral; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors	2012
Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy. Nature reviews. Gastroenterology & hepatology, 2011, Dec-20, Volume: 9, Issue:2 Topics: Antiviral Agents; Contraindications; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; RNA, Viral; Standard of Care	2011
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Withholding Treatment	2012
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indiana; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load	2012
Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Treatment Failure; Treatment Outcome; Virus Replication; Young Adult	2012
Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Standard of Care; Treatment Failure	2012
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Algorithms; Anemia; Antiviral Agents; Clinical Protocols; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Time Factors; Viral Load	2012
Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'? Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load	2012
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Disease Eradication; Drug Administration Schedule; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome	2012
Future treatment of patients with HCV cirrhosis. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load	2012
Hepatitis C virus treatment pre- and post-liver transplantation. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load	2012
Hepatitis C virus-human immunodeficiency virus coinfection. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load	2012
What's new in HCV genotype 2 treatment. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2012
Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load	2012
The future for the treatment of genotype 4 chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Albumins; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Thiazoles; Time Factors; Viral Load; Vitamin D	2012
Barriers to hepatitis C treatment. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Refusal; Viral Load	2012
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Zeitschrift fur Gastroenterologie, 2012, Volume: 50, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors	2012
Treatment failure with new hepatitis C drugs. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Phenotype; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure	2012
Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients. Clinics and research in hepatology and gastroenterology, 2011, Volume: 35 Suppl 2 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins	2011
Antiviral strategies in hepatitis C virus infection. Journal of hepatology, 2012, Volume: 56 Suppl 1 Topics: Antiviral Agents; Cyclophilins; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins	2012
IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2011, Volume: 49, Issue:2 Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Sensitivity and Specificity; Treatment Outcome	2011
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:5 Topics: Anti-Retroviral Agents; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Male; Oligopeptides; Proline; Risk Assessment; Treatment Outcome	2012
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. Swiss medical weekly, 2012, Volume: 142 Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; RNA, Viral; Treatment Outcome	2012
Protease inhibitors: silver bullets for chronic hepatitis C infection? Cleveland Clinic journal of medicine, 2012, Volume: 79, Issue:3 Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins	2012
Hepatitis C and substance use: new treatments and novel approaches. Current opinion in psychiatry, 2012, Volume: 25, Issue:3 Topics: Antiviral Agents; Attitude of Health Personnel; Drug Therapy, Combination; Health Services Accessibility; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors; Substance-Related Disorders	2012
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. Journal of viral hepatitis, 2012, Volume: 19 Suppl 2 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors; Viremia	2012
Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C? Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:1 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Liver Neoplasms; North America; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome; Viral Load	2012
Resistance to anti-HCV protease inhibitors. Current opinion in virology, 2011, Volume: 1, Issue:6 Topics: Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Molecular; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins; Virus Replication	2011
Hepatitis C therapy update. Current opinion in gastroenterology, 2012, Volume: 28, Issue:3 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors	2012
Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Current opinion in organ transplantation, 2012, Volume: 17, Issue:3 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin	2012
Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clinics and research in hepatology and gastroenterology, 2012, Volume: 36, Issue:5 Topics: Drug Eruptions; Genotype; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors	2012
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut, 2012, Volume: 61 Suppl 1 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Serine Proteinase Inhibitors	2012
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Disease Management; Disease Progression; Drug Interactions; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load	2012
HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:8 Topics: Coinfection; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Oligopeptides; Proline; Serine Proteinase Inhibitors	2012
Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:1 Topics: Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Oligopeptides; Polymorphism, Genetic; Proline; Treatment Outcome	2012
New virologic tools for management of chronic hepatitis B and C. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Point-of-Care Systems; Polyethylene Glycols; Proline; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome	2012
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Tract; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome	2012
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome	2012
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. The Lancet. Infectious diseases, 2012, Volume: 12, Issue:9 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; United States	2012
Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:1 Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors; Treatment Outcome	2013
[Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively]. Przeglad epidemiologiczny, 2012, Volume: 66, Issue:1 Topics: Antiviral Agents; Carrier Proteins; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Oligopeptides; Poland; Proline; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins	2012
New pharmacotherapy for hepatitis C. Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:3 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver; Oligopeptides; Proline	2012
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:10 Topics: Antiviral Agents; Drug Combinations; France; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors	2012
[Chronic hepatitis C: improved cure rates with new approved medications]. MMW Fortschritte der Medizin, 2012, Jun-21, Volume: O 154 Suppl 2 Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; Genotype; Guideline Adherence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2012
Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Current medical research and opinion, 2012, Volume: 28, Issue:11 Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Randomized Controlled Trials as Topic	2012
A new era in the treatment of chronic hepatitis C infection. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2013, Volume: 32, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2013
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:2 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Recurrence; Treatment Outcome	2013
[Management of chronic hepatitis C in 2012 in Belgium]. Revue medicale de Bruxelles, 2012, Volume: 33, Issue:4 Topics: Antiviral Agents; Belgium; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Humans; Models, Biological; Oligopeptides; Proline	2012
Interferon stimulated genes and hepatitis C virus infection. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2012, Volume: 32, Issue:12 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Nonstructural Proteins	2012
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:2 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
Management of the transplant recipient with chronic hepatitis C. Clinics in liver disease, 2013, Volume: 17, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferons; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Care; Preoperative Care; Proline; Ribavirin; Serine Proteinase Inhibitors	2013
Telaprevir/boceprevir era: from bench to bed and back. World journal of gastroenterology, 2012, Nov-21, Volume: 18, Issue:43 Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Translational Research, Biomedical; Treatment Outcome	2012
Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antiviral therapy, 2012, Volume: 17, Issue:6 Pt B Topics: Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Economic; Oligopeptides; Proline; Treatment Outcome; United States	2012
Future perspectives: towards interferon-free regimens for HCV. Antiviral therapy, 2012, Volume: 17, Issue:6 Pt B Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2012
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antiviral therapy, 2012, Volume: 17, Issue:6 Pt B Topics: Algorithms; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Serine Proteinase Inhibitors; Viral Nonstructural Proteins	2012
Immunology of hepatitis C virus infections. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4 Topics: Adaptive Immunity; Antiviral Agents; Dendritic Cells; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Killer Cells, Natural; Liver; Oligopeptides; Proline; T-Lymphocytes	2012
Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2012
The role of resistance in HCV treatment. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Microbial Sensitivity Tests; Molecular Targeted Therapy; Mutation; Oligopeptides; Proline; Protease Inhibitors; Ribavirin	2012
IL28B in the era of direct-acting antivirals for hepatitis C. Journal of clinical gastroenterology, 2013, Volume: 47, Issue:3 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Oligopeptides; Proline; Time Factors; Treatment Outcome	2013
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clinical therapeutics, 2013, Volume: 35, Issue:2 Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin	2013
Anemia management in patients with chronic viral hepatitis C. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:2 Topics: Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Hematinics; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Viral Nonstructural Proteins	2013
[Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2012, Volume: 57, Issue:9-10 Topics: Antiviral Agents; Drug Interactions; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline	2012
Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clinical drug investigation, 2013, Volume: 33, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Odds Ratio; Oligopeptides; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
HCV RNA viral load assessments in the era of direct-acting antivirals. The American journal of gastroenterology, 2013, Volume: 108, Issue:4 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors; Real-Time Polymerase Chain Reaction; RNA, Viral; Viral Load	2013
Hepatitis C virus therapy update 2013. Current opinion in gastroenterology, 2013, Volume: 29, Issue:3 Topics: Antiviral Agents; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors	2013
Emerging therapeutic targets for hepatitis C virus infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:6 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin	2013
[Progress in hepatitis C treatment]. Medicina clinica, 2013, Nov-16, Volume: 141, Issue:10 Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia	2013
Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Current opinion in organ transplantation, 2013, Volume: 18, Issue:3 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Oligopeptides; Postoperative Care; Preoperative Care; Proline; Protease Inhibitors	2013
Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC gastroenterology, 2013, May-14, Volume: 13 Topics: Antiviral Agents; Contraindications; Drug Interactions; Hepatitis C; Humans; Medication Adherence; Mental Disorders; Oligopeptides; Proline; Psychotropic Drugs	2013
Evolution of cell culture systems for HCV. Antiviral therapy, 2013, Volume: 18, Issue:3 Pt B Topics: Antiviral Agents; Cell Culture Techniques; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Virus Cultivation; Virus Replication	2013
Protease inhibitors for hepatitis C: economic implications. PharmacoEconomics, 2013, Volume: 31, Issue:9 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality of Life; Recombinant Proteins; Ribavirin	2013
Drug-drug interactions in the treatment of HCV among people who inject drugs. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 57 Suppl 2 Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Substance Abuse, Intravenous	2013
[Treatment of chronic hepatitis C virus infection at the beginning of a new era]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:7 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Polyethylene Glycols; Proline	2013
Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2013, Volume: 26, Issue:3 Topics: Antiviral Agents; Drug Interactions; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Monitoring, Physiologic; Oligopeptides; Patient Selection; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic	2013
Optimizing DAA management in daily practice. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Antiviral Agents; Checklist; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Medication Adherence; Oligopeptides; Patient Education as Topic; Polyethylene Glycols; Proline; Ribavirin	2013
Management of anaemia and other treatment complications. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Anemia; Antiviral Agents; Contraindications; Drug Eruptions; Drug Therapy, Combination; Dysgeusia; Hemorrhoids; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Patient Selection; Platelet Count; Polyethylene Glycols; Proline; Pruritus Ani; Ribavirin; Serum Albumin	2013
The importance of drug-drug interactions in the DAA era. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Antiviral Agents; Contraindications; Cytochrome P-450 CYP3A; Databases, Pharmaceutical; Drug Interactions; Hepatitis C, Chronic; Humans; Internet; Oligopeptides; Proline	2013
Treatment of chronic hepatitis C virus infection after liver transplantation. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Antiviral Agents; Drug Interactions; End Stage Liver Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Proline; Ribavirin; Secondary Prevention	2013
Optimizing treatment in HIV/HCV coinfection. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Anti-Retroviral Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin	2013
Safety of direct antiviral agents in real life. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors	2013
Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1 Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin	2014
Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients. Journal of clinical gastroenterology, 2014, Volume: 48, Issue:2 Topics: Aminoisobutyric Acids; Antiviral Agents; Coinfection; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferons; Leucine; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Simeprevir; Sulfonamides; Thiazoles; Viral Nonstructural Proteins	2014
Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. International journal of antimicrobial agents, 2014, Volume: 43, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline	2014
Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:1 Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Virus Activation	2014
Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:1 Topics: Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline	2014
An overview of emerging therapies for the treatment of chronic hepatitis C. The Medical clinics of North America, 2014, Volume: 98, Issue:1 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Metabolic Networks and Pathways; Oligopeptides; Pharmacogenetics; Proline; Therapies, Investigational; Viral Hepatitis Vaccines; Virus Physiological Phenomena	2014
Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. Journal of hepatology, 2014, Volume: 60, Issue:4 Topics: Administration, Oral; Anti-Bacterial Agents; Antiviral Agents; Calcineurin Inhibitors; Chemical and Drug Induced Liver Injury; Drug Interactions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Transplantation; Oligopeptides; Proline; Risk Factors; Tacrolimus; TOR Serine-Threonine Kinases	2014
[Hepatitis C virus: 25 years-old, the end?]. Medecine sciences : M/S, 2013, Volume: 29, Issue:11 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin	2013
How to optimize current therapy of HCV genotype 1 infection with boceprevir. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Risk Assessment; Treatment Outcome	2014
Management of HCV patients with cirrhosis with direct acting antivirals. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate	2014
Management of HCV transplant patients with triple therapy. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Antiviral Agents; Disease Management; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Oligopeptides; Proline; Secondary Prevention; Treatment Outcome	2014
Treating HCV in HIV 2013: on the cusp of change. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine	2014
[The role of hepcidin and polymorphisms in the regulatory region of the IL-28B gene in HCV infections]. Postepy higieny i medycyny doswiadczalnej (Online), 2013, Dec-11, Volume: 67 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Hepcidins; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polymorphism, Genetic; Prognosis; Proline; Protease Inhibitors; Regulatory Sequences, Nucleic Acid; Ribavirin; Treatment Outcome	2013
[Hepatitis C update: what has changed? What can we expect in the near future?]. MMW Fortschritte der Medizin, 2013, Nov-07, Volume: 155, Issue:19 Topics: Antiviral Agents; Cross-Sectional Studies; Drug Approval; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Drugs, Investigational; Germany; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Prognosis; Proline; Protease Inhibitors	2013
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. Journal of viral hepatitis, 2014, Volume: 21, Issue:4 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Species Specificity; Treatment Outcome	2014
Hepatitis C treatment: an incipient therapeutic revolution. Trends in molecular medicine, 2014, Volume: 20, Issue:6 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate	2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clinical pharmacokinetics, 2014, Volume: 53, Issue:5 Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PloS one, 2014, Volume: 9, Issue:4 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2014
Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors. Przeglad epidemiologiczny, 2013, Volume: 67, Issue:4 Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Poland; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin	2013
Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert review of pharmacoeconomics & outcomes research, 2014, Volume: 14, Issue:3 Topics: Cost-Benefit Analysis; Drug Labeling; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Quality-Adjusted Life Years	2014
Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? European journal of clinical pharmacology, 2014, Volume: 70, Issue:7 Topics: Animals; Antiviral Agents; Arrhythmias, Cardiac; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Food-Drug Interactions; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors	2014
Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:8 Topics: Antiviral Agents; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Treatment Outcome; Viral Load; Virus Replication	2014
Hepatitis C in HIV-infected patients: impact of direct-acting antivirals. Drugs, 2014, Volume: 74, Issue:9 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline	2014
Emerging therapeutic options for the management of hepatitis C infection. World journal of gastroenterology, 2014, Jun-21, Volume: 20, Issue:23 Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; RNA-Dependent RNA Polymerase; Treatment Outcome; Viral Nonstructural Proteins; Virus Replication	2014
Treating hepatitis C in the elderly: the future is near? Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2014
Decade in review-HCV: hepatitis C therapy-a fast and competitive race. Nature reviews. Gastroenterology & hepatology, 2014, Volume: 11, Issue:11 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2014
Emerging treatments for chronic hepatitis C. Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:3 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline	2015
Hepatitis C management in post-transplant patients. Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:1 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load	2015
Which therapeutic option for hepatitis C virus genotype 1? Scandinavian journal of gastroenterology, 2015, Volume: 50, Issue:4 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Oligopeptides; Proline; Randomized Controlled Trials as Topic; Simeprevir; Sofosbuvir; Viral Load	2015
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. Journal of hepatology, 2014, Volume: 61, Issue:1 Suppl Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins	2014
[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline]. Orvosi hetilap, 2015, Mar-01, Volume: 156, Issue:9 Topics: Antiviral Agents; Consensus; Disease Progression; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Hungary; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Registries; Ribavirin; Treatment Outcome	2015
Management of post transplant hepatitis C in the direct antiviral agents era. Hepatology international, 2015, Volume: 9, Issue:2 Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins	2015
A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. Journal of comparative effectiveness research, 2015, Volume: 4, Issue:2 Topics: Algorithms; Antiviral Agents; Bayes Theorem; Comparative Effectiveness Research; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2015
Management of HCV in cirrhosis-a rapidly evolving landscape. Current gastroenterology reports, 2015, Volume: 17, Issue:5 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline	2015
[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice]. Gastroenterologia y hepatologia, 2014, Volume: 37 Suppl 1 Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Metabolic Syndrome; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Risk Factors	2014
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus. Journal of medical economics, 2015, Volume: 18, Issue:10 Topics: Antiviral Agents; Clinical Trials as Topic; Databases, Bibliographic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Viral Load	2015
[Significance of hepatitis C virus baseline polymorphism during the antiviral therapy]. Orvosi hetilap, 2015, May-24, Volume: 156, Issue:21 Topics: Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Oligopeptides; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Virus Replication	2015
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:8 Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load	2017
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. BMC gastroenterology, 2017, Nov-23, Volume: 17, Issue:1 Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine	2017

Trials

28 trial(s) available for proline and telaprevir

Article	Year
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:6 Topics: Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Models, Theoretical; Mutation; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Viral Nonstructural Proteins	2009
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2011, Volume: 52, Issue:4 Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Longitudinal Studies; Mutation, Missense; Oligopeptides; Proline; RNA, Viral; Sequence Analysis, DNA; Viral Nonstructural Proteins	2011
Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. Journal of acquired immune deficiency syndromes (1999), 2012, Nov-01, Volume: 61, Issue:3 Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin	2012
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PloS one, 2013, Volume: 8, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Platelet Count; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome	2013
Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Journal of hepatology, 2013, Volume: 59, Issue:1 Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Replicon; RNA, Viral; Viral Load; Viral Nonstructural Proteins	2013
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the rheumatic diseases, 2014, Volume: 73, Issue:5 Topics: Aged; Antiviral Agents; Cohort Studies; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Vasculitis	2014
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. Journal of hepatology, 2013, Volume: 59, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load	2013
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:7 Topics: Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2013
Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:1 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Renal Insufficiency	2014
The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. Journal of acquired immune deficiency syndromes (1999), 2014, Apr-15, Volume: 65, Issue:5 Topics: Adolescent; Adult; Antiviral Agents; Cyclohexanes; Healthy Volunteers; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Proline; Triazoles; Young Adult	2014
Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. British journal of clinical pharmacology, 2014, Volume: 78, Issue:5 Topics: Adult; Aged; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Heterocyclic Compounds, 3-Ring; HIV; Humans; Male; Metabolic Clearance Rate; Middle Aged; Oligopeptides; Oxazines; Piperazines; Proline; Pyridones; Young Adult	2014
High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2 Topics: Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load	2015
HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. Antiviral therapy, 2015, Volume: 20, Issue:2 Topics: 2-Naphthylamine; Antiviral Agents; Biological Assay; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Oligopeptides; Polyethylene Glycols; Proline; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Uracil; Viral Load	2015
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:9 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kinetics; Male; Middle Aged; Models, Biological; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Treatment Outcome	2014
eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Age Factors; Antiviral Agents; ErbB Receptors; Hepatitis C; Humans; Interferon-alpha; Kidney; Linear Models; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors	2015
Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11 Topics: Adult; Area Under Curve; Benzoates; Calcium; Cross-Over Studies; Diet; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Oligopeptides; Proline; Purpura, Thrombocytopenic; Pyrazoles; Receptors, Thrombopoietin; Serine Proteinase Inhibitors; Young Adult	2014
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. Journal of hepatology, 2015, Volume: 62, Issue:2 Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult	2015
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:7 Topics: Aged; Antiviral Agents; Area Under Curve; beta 2-Glycoprotein I; Biomarkers; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Virus Replication	2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:7 Topics: Adolescent; Adult; Age Factors; Aged; Algorithms; Antiviral Agents; Biomarkers; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult	2015
Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. Zeitschrift fur Gastroenterologie, 2015, Volume: 53, Issue:7 Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Evidence-Based Medicine; Female; Germany; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2015
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PloS one, 2016, Volume: 11, Issue:1 Topics: Adult; Antibodies, Viral; Antimetabolites; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2016
Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring. Clinics and research in hepatology and gastroenterology, 2016, Volume: 40, Issue:5 Topics: Antiviral Agents; Drug Monitoring; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Ribavirin	2016
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PloS one, 2016, Volume: 11, Issue:3 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Elastase; Male; Middle Aged; Neutrophils; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome	2016
Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1. Journal of gastrointestinal and liver diseases : JGLD, 2016, Volume: 25, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Smoking; Time Factors; Treatment Outcome; Viral Load; Young Adult	2016
Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. PloS one, 2016, Volume: 11, Issue:10 Topics: Anemia; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Mood Disorders; Oligopeptides; Proline; Ribavirin; Severity of Illness Index; Treatment Outcome	2016
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). The patient, 2017, Volume: 10, Issue:5 Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Comorbidity; Double-Blind Method; Female; Fluorenes; Health Status; Hepatitis C, Chronic; Humans; Male; Mental Health; Middle Aged; Oligopeptides; Patient Reported Outcome Measures; Polyethylene Glycols; Proline; Quality of Life; Severity of Illness Index; Sex Factors; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2017
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics (Sao Paulo, Brazil), 2017, Volume: 72, Issue:6 Topics: Aged; Antiviral Agents; Brazil; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; RNA, Viral; Treatment Outcome	2017
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir. Revista do Instituto de Medicina Tropical de Sao Paulo, 2018, Volume: 60 Topics: Antiviral Agents; Clinical Protocols; Decision Making; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin	2018

Other Studies

223 other study(ies) available for proline and telaprevir

Article	Year
Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antiviral chemistry & chemotherapy, 2007, Volume: 18, Issue:3 Topics: Animals; Antiviral Agents; Hepacivirus; Humans; Male; Microsomes, Liver; Models, Animal; Oligopeptides; Plasma; Proline; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Ritonavir	2007
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology, 2008, Jan-20, Volume: 370, Issue:2 Topics: Adult; Amino Acid Sequence; Base Sequence; Carbamates; DNA, Viral; Drug Resistance, Viral; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Macrocyclic Compounds; Male; Molecular Sequence Data; Oligopeptides; Point Mutation; Proline; Quinolines; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Serine Endopeptidases; Serine Proteinase Inhibitors; Thiazoles; Viral Nonstructural Proteins	2008
Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral research, 2008, Volume: 77, Issue:3 Topics: Antiviral Agents; Carrier Proteins; Drug Resistance, Viral; Hepacivirus; Humans; Intracellular Signaling Peptides and Proteins; Models, Molecular; Molecular Structure; Mutation, Missense; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins; Viral Proteins; Virus Replication	2008
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008]. Orvosi hetilap, 2008, Jul-13, Volume: 149, Issue:28 Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib	2008
Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antiviral therapy, 2008, Volume: 13, Issue:4 Topics: Amino Acid Sequence; Antiviral Agents; Carbamates; Carrier Proteins; Drug Resistance, Viral; Global Health; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Macrocyclic Compounds; Microbial Sensitivity Tests; Molecular Sequence Data; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Quinolines; Sequence Alignment; Thiazoles; Viral Nonstructural Proteins; Viral Proteins	2008
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:6 Topics: Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genetic Testing; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Male; Mutation; Oligopeptides; Phenylthiourea; Phylogeny; Proline; Protease Inhibitors; Quinolines; Thiazoles; Viral Load; Viral Nonstructural Proteins	2008
Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors. Current gastroenterology reports, 2009, Volume: 11, Issue:1 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication	2009
Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic acids research, 2009, Volume: 37, Issue:10 Topics: Antiviral Agents; DNA Mutational Analysis; Drug Resistance, Viral; Mutation; Oligopeptides; Proline; Serine Endopeptidases; Serine Proteinase Inhibitors; Viral Nonstructural Proteins	2009
HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism. Biochimica et biophysica acta, 2009, Volume: 1794, Issue:10 Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Half-Life; Hepacivirus; Humans; Kinetics; Macrocyclic Compounds; Models, Biological; Mutation; Oligopeptides; Proline; Quinolines; Recombinant Proteins; Serine Endopeptidases; Serine Proteinase Inhibitors; Thiazoles; Viral Nonstructural Proteins	2009
Hepatitis C drug development at a crossroads. Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2009
Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Dec-01, Volume: 877, Issue:31 Topics: Antiviral Agents; Chromatography, Liquid; Hepacivirus; Humans; Oligopeptides; Peptide Hydrolases; Proline; Protease Inhibitors; Reference Standards; Tandem Mass Spectrometry	2009
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:6 Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline	2010
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. Journal of viral hepatitis, 2011, Volume: 18, Issue:5 Topics: Antiviral Agents; Blood Proteins; Carbamates; Cell Line; Comparative Effectiveness Research; Dialysis; Hepacivirus; Hepatitis C; Humans; Inhibitory Concentration 50; Macrocyclic Compounds; Membranes, Artificial; Oligopeptides; Phenylthiourea; Plasma; Proline; Protease Inhibitors; Protein Binding; Quinolines; RNA, Viral; Thiazoles; Viral Load	2011
Excitement grows for potential revolution in hepatitis C virus treatment. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:7 Topics: Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors	2010
STAT-C: a full revolution or just a step forward? Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Virus Replication	2010
On the cusp of change: new therapeutic modalities for HCV. Annals of hepatology, 2010, Volume: 9 Suppl Topics: Antiviral Agents; Clinical Trials as Topic; Drug Costs; Drug Therapy, Combination; Drugs, Investigational; Evidence-Based Medicine; Hepatitis C; Humans; Oligopeptides; Patient Selection; Proline; Treatment Outcome; Viral Load	2010
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Caco-2 Cells; Carrier Proteins; Cell Line, Tumor; Hepacivirus; Humans; Intracellular Signaling Peptides and Proteins; Leucine; Male; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Rats; Thiazoles; Viral Nonstructural Proteins; Viral Proteins; Virus Replication	2010
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12 Topics: Antiviral Agents; Cell Line, Tumor; Cyclopropanes; Hepacivirus; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Molecular Structure; Oligopeptides; Proline; Protease Inhibitors; Simeprevir; Sulfonamides	2010
Big changes are coming in hepatitis C. Current gastroenterology reports, 2011, Volume: 13, Issue:1 Topics: Administration, Oral; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin	2011
The role of triple therapy in HCV genotype 1-experienced patients. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2011
The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology, 2011, Volume: 140, Issue:3 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load	2011
Drugs in development for viral hepatitis: care and caution. Drugs, 2011, Feb-12, Volume: 71, Issue:3 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis, Viral, Human; Humans; Oligopeptides; Proline	2011
Infectious diseases. First specific drugs raise hopes for hepatitis C. Science (New York, N.Y.), 2011, Apr-08, Volume: 332, Issue:6026 Topics: Antiviral Agents; Clinical Trials as Topic; Developing Countries; Drug Approval; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Viral Nonstructural Proteins	2011
Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4 Topics: Amino Acid Substitution; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; Inhibitory Concentration 50; Isoindoles; Lactams; Lactams, Macrocyclic; Oligopeptides; Proline; Protease Inhibitors; Sulfonamides; Viral Nonstructural Proteins; Virus Replication	2011
Distributive justice and the arrival of direct-acting antivirals: who should be first in line? Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:6 Topics: Algorithms; Antiviral Agents; Health Care Rationing; Hepatitis C; Humans; Oligopeptides; Proline; Resource Allocation; United States; United States Food and Drug Administration	2011
Introduction: a smouldering public-health crisis. Nature, 2011, Jun-08, Volume: 474, Issue:7350 Topics: Adolescent; France; Global Health; Hepacivirus; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline; Public Health; Viral Hepatitis Vaccines; Young Adult	2011
Therapeutics: new drugs hit the target. Nature, 2011, Jun-08, Volume: 474, Issue:7350 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin; Simeprevir; Sulfonamides	2011
Perspective: miles to go before we sleep. Nature, 2011, Jun-08, Volume: 474, Issue:7350 Topics: Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Time Factors	2011
Two drugs approved for chronic hepatitis C infection. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011, Jul-01, Volume: 68, Issue:13 Topics: Antiviral Agents; Drugs, Investigational; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors	2011
Viral hepatitis: progress and promise. Nature reviews. Gastroenterology & hepatology, 2011, Volume: 8, Issue:5 Topics: Antiviral Agents; Hepatitis B; Hepatitis C; Humans; Oligopeptides; Patient Compliance; Pharmacogenetics; Proline; Treatment Outcome	2011
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology, 2011, Volume: 141, Issue:3 Topics: Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Molecular Sequence Data; Oligopeptides; Proline; Protease Inhibitors; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins	2011
Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:1 Topics: Antiviral Agents; Cyclosporine; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Hepatitis C; Humans; Immunosuppressive Agents; Liver Transplantation; Oligopeptides; Proline; Tacrolimus	2011
The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. Journal of hepatology, 2012, Volume: 56, Issue:2 Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Medication Adherence; Oligopeptides; Proline	2012
New Merck and Vertex drugs raise standard of care in hepatitis C. Nature biotechnology, 2011, Jul-11, Volume: 29, Issue:7 Topics: Antiviral Agents; Drug Industry; Hepatitis C; Humans; Oligopeptides; Proline; Quality of Health Care; United States	2011
Boceprevir for chronic HCV genotype 1 infection. The New England journal of medicine, 2011, 07-14, Volume: 365, Issue:2 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Load	2011
Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. The Medical letter on drugs and therapeutics, 2011, Jul-25, Volume: 53, Issue:1369 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2011
HCV protease inhibitors bring new options for patients. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011, Aug-01, Volume: 68, Issue:15 Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Virus Replication	2011
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Antiviral therapy, 2011, Volume: 16, Issue:5 Topics: Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Time Factors; Viral Load	2011
Going viral. Scientific American, 2011, Volume: 305, Issue:2 Topics: Anti-HIV Agents; Drug Approval; Hepatitis C; Humans; Oligopeptides; Proline	2011
[A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)]. MMW Fortschritte der Medizin, 2011, Jul-21, Volume: 153, Issue:29-31 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Precision Medicine; Proline; Protease Inhibitors	2011
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:4 Topics: Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Prognosis; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Societies, Medical; Treatment Outcome; United States	2011
Will direct-acting antivirals make a difference in HIV-HCV coinfected patients? Expert review of anti-infective therapy, 2011, Volume: 9, Issue:9 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Coinfection; Drug Interactions; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Serine Proteases; Serine Proteinase Inhibitors; Viral Proteins	2011
[New treatments for hepatitis C, which targets, what timeline?]. Revue medicale suisse, 2011, Sep-07, Volume: 7, Issue:307 Topics: Antiviral Agents; Hepatitis C; Humans; Oligopeptides; Proline	2011
[New triple therapy in chronic hepatitis C. Increased patient chances]. MMW Fortschritte der Medizin, 2011, Sep-29, Volume: 153, Issue:39 Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; RNA, Viral	2011
The expanding role of the pharmacist in the management of hepatitis C infection. Journal of managed care pharmacy : JMCP, 2011, Volume: 17, Issue:9 Topics: Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline; Protease Inhibitors	2011
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:4 Topics: Antiviral Agents; Biomarkers; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Decision Making; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Predictive Value of Tests; Proline; Retrospective Studies; RNA, Viral; Treatment Outcome	2012
Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. Journal of clinical microbiology, 2012, Volume: 50, Issue:2 Topics: Adult; Antiviral Agents; Biota; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Oligopeptides; Polymerase Chain Reaction; Proline; Virology	2012
Protease inhibitors in hepatitis C: from chronic disease to cure. Irish medical journal, 2011, Volume: 104, Issue:8 Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors	2011
New HCV drugs trigger race for more tolerable therapies. Nature medicine, 2011, Dec-06, Volume: 17, Issue:12 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Industry; Drug Resistance, Multiple, Viral; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline	2011
Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease. Gastroenterology, 2012, Volume: 142, Issue:3 Topics: Antiviral Agents; Binding Sites; Carrier Proteins; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Drug Resistance, Viral; Hepacivirus; Humans; Intracellular Signaling Peptides and Proteins; Ligands; Models, Molecular; Molecular Structure; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Protein Conformation; Time Factors; Transfection; Viral Nonstructural Proteins; Virus Replication	2012
Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 54, Issue:7 Topics: Antiviral Agents; Genotype; Guidelines as Topic; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Oligopeptides; Proline; Protease Inhibitors; United States	2012
A major advance in treating hepatitis C. The Johns Hopkins medical letter health after 50, 2011, Volume: 23, Issue:10 Topics: Antiviral Agents; Drug Administration Schedule; Drug Approval; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; United States; United States Food and Drug Administration	2011
New developments in HCV therapy. Journal of viral hepatitis, 2012, Volume: 19 Suppl 1 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Treatment Outcome; Viral Nonstructural Proteins	2012
Direct-acting antiviral (DAA) actions in treatment-naïve patients. Clinics and research in hepatology and gastroenterology, 2011, Volume: 35 Suppl 2 Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors	2011
New hepatitis C regimen stimulates changes in therapy management. Managed care (Langhorne, Pa.), 2011, Volume: 20, Issue:12 Topics: Anemia; Antiviral Agents; Disease Management; Drug Interactions; Hematinics; Hepatitis C; Humans; Oligopeptides; Proline; Protease Inhibitors; Standard of Care	2011
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:6 Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; United Kingdom; Viral Load	2012
[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)]. Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:5 Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2012
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. Orvosi hetilap, 2012, Mar-11, Volume: 153, Issue:10 Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Guanine; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Hungary; Interferon-alpha; Interferons; Lamivudine; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome	2012
[Current indications for triple therapy in hepatitis C virus infection]. Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2012
Triple therapy for hepatitis C. JAAPA : official journal of the American Academy of Physician Assistants, 2012, Volume: 25, Issue:2 Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Oligopeptides; Proline	2012
[New times for the treatment of chronic hepatitis C]. Ugeskrift for laeger, 2012, Mar-19, Volume: 174, Issue:12 Topics: Antiviral Agents; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors; Virus Replication	2012
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:3 Topics: Cost-Benefit Analysis; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline	2012
Targeted therapies for hepatitis C reach the clinic. Chemistry & biology, 2012, Apr-20, Volume: 19, Issue:4 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline	2012
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. The American journal of gastroenterology, 2012, Volume: 107, Issue:5 Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Risk Factors	2012
Genetic factors and hepatitis C virus infection. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Antiviral Agents; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome	2012
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy]. Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:9 Topics: Antiviral Agents; Biopsy; Contraindications; Diagnostic Imaging; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon Type I; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Patient Care Team; Polyethylene Glycols; Proline; Protease Inhibitors; Recurrence; Ribavirin; Viral Load	2012
New genetic discoveries and treatment for hepatitis C. JAMA, 2012, May-09, Volume: 307, Issue:18 Topics: Antiviral Agents; DNA, Viral; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Proline; Recombinant Proteins; Ribavirin	2012
Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bulletin of mathematical biology, 2012, Volume: 74, Issue:8 Topics: Cell Proliferation; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Models, Genetic; Mutation; Numerical Analysis, Computer-Assisted; Oligopeptides; Proline; Protease Inhibitors	2012
Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 1 Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; MicroRNAs; Oligopeptides; Proline; Protease Inhibitors; Treatment Outcome; Viral Nonstructural Proteins; Virus Replication	2012
Effect of discounting on estimation of benefits determined by hepatitis C treatment. World journal of gastroenterology, 2012, Jun-21, Volume: 18, Issue:23 Topics: Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Markov Chains; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin	2012
Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers. Southern medical journal, 2012, Volume: 105, Issue:8 Topics: Antiviral Agents; Black or African American; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Research Subjects; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Failure	2012
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors. Acta gastro-enterologica Belgica, 2012, Volume: 75, Issue:2 Topics: Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors	2012
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS pathogens, 2012, Volume: 8, Issue:7 Topics: Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Indoles; Isoindoles; Lactams; Lactams, Macrocyclic; Leucine; Models, Molecular; Oligopeptides; Proline; Protease Inhibitors; Protein Structure, Tertiary; Structure-Activity Relationship; Sulfonamides; Viral Nonstructural Proteins	2012
[Treatment of chronic hepatitis C in HIV coinfection]. MMW Fortschritte der Medizin, 2012, May-16, Volume: 154 Suppl 1 Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Oligopeptides; Proline; Serine Proteinase Inhibitors	2012
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut, 2012, Volume: 61, Issue:12 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure	2012
[Treatment of chronic hepatitis viral C: new associations]. Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:6 Pt 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2013
Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? Journal of hepatology, 2013, Volume: 58, Issue:2 Topics: Antiviral Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome	2013
Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection. Infectious disease clinics of North America, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Recurrence; Ribavirin; RNA, Viral; Viral Load	2012
Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era. Infectious disease clinics of North America, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C; HIV Infections; Humans; Oligopeptides; Proline	2012
The changing face of hepatitis C in the new era of direct-acting antivirals. Antiviral research, 2013, Volume: 97, Issue:1 Topics: Antiviral Agents; Asymptomatic Diseases; Carrier State; Health Services Accessibility; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Treatment Outcome	2013
Telaprevir to boceprevir switch highlights lack of cross-reactivity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:4 Topics: Antiviral Agents; Cross Reactions; Drug Substitution; Eosinophilia; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; RNA, Viral; Viral Load	2013
[Prevalence of potential interactions between antiretroviral therapy and boceprevir or telaprevir in human immunodeficiency virus-hepatitis C virus coinfected patients]. Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31, Issue:5 Topics: Adult; Aged; Anti-Retroviral Agents; Coinfection; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies	2013
Hepatitis C in 2012. South Dakota medicine : the journal of the South Dakota State Medical Association, 2012, Volume: 65, Issue:11 Topics: Antiviral Agents; Drug Therapy, Combination; Gastroenterology; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin	2012
Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient. Expert review of anti-infective therapy, 2012, Volume: 10, Issue:10 Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials, Phase II as Topic; Coinfection; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Oligopeptides; Proline; Treatment Outcome	2012
Triple therapy with boceprevir or telaprevir for prior HCV non-responders. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Ribavirin	2012
[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver]. Harefuah, 2012, Volume: 151, Issue:12 Topics: Antiviral Agents; Drug Approval; Drug Design; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-Stimulated Gene Factor 3, gamma Subunit; Oligopeptides; Proline	2012
Is the HCV pipeline heading in the right direction? Gastroenterology, 2013, Volume: 144, Issue:3 Topics: Antiviral Agents; Coinfection; Drug Discovery; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Off-Label Use; Oligopeptides; Proline; Treatment Outcome	2013
Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:10 Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Limit of Detection; Oligopeptides; Proline; Retrospective Studies; RNA, Viral; Treatment Outcome; Viral Load	2013
Current management of hepatitis C virus infection in patients with HIV co-infection. The Journal of infectious diseases, 2013, Volume: 207 Suppl 1 Topics: Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Male; Oligopeptides; Proline; Treatment Outcome	2013
The FDA, bridging data, and hepatitis C. Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:3 Topics: Antiviral Agents; Drug Approval; Drug Monitoring; Hepatitis C, Chronic; Humans; Oligopeptides; Proline	2013
Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology, 2013, Volume: 144, Issue:7 Topics: Adolescent; Adult; Albumins; Antiviral Agents; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Endpoint Determination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load	2013
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. Journal of pharmaceutical and biomedical analysis, 2013, May-05, Volume: 78-79 Topics: Chromatography, Liquid; Hepatitis C; Humans; Isomerism; Limit of Detection; Oligopeptides; Proline; Protease Inhibitors; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry	2013
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:8 Topics: Aged; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Treatment Outcome; Veterans; Viral Load	2013
What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind. Journal of viral hepatitis, 2013, Volume: 20, Issue:5 Topics: Antiviral Agents; Developing Countries; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Pakistan; Proline	2013
A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:8 Topics: Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States	2013
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7 Topics: Antiviral Agents; Chromatography, Liquid; Drug Monitoring; Hepacivirus; Hepatitis; Humans; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Tandem Mass Spectrometry	2013
Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antiviral therapy, 2013, Volume: 18, Issue:5 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Treatment Outcome; Viral Load; Young Adult	2013
Telaprevir and boceprevir: a potential role for therapeutic drug monitoring. Therapeutic drug monitoring, 2013, Volume: 35, Issue:3 Topics: Antiviral Agents; Area Under Curve; Drug Monitoring; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Protease Inhibitors	2013
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:11 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Expectancy; Male; Middle Aged; Oligopeptides; Proline; Quality of Life; Ribavirin; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health	2013
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. Journal of hepatology, 2013, Volume: 59, Issue:4 Topics: Antiviral Agents; Cost-Benefit Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Oligopeptides; Proline; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Failure	2013
Mixed genotype hepatitis C infections and implications for treatment. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Oligopeptides; Prevalence; Proline	2014
Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment. American journal of clinical dermatology, 2013, Volume: 14, Issue:6 Topics: Antiviral Agents; Drug Eruptions; Drug Hypersensitivity Syndrome; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Severity of Illness Index	2013
Rapid progression of antiviral treatments of chronic hepatitis C virus infection. Minerva gastroenterologica e dietologica, 2013, Volume: 59, Issue:2 Topics: Administration, Oral; Antiviral Agents; Drug Prescriptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Time Factors	2013
Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2013, Volume: 27, Issue:7 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Indians, North American; Male; Manitoba; Middle Aged; Mutation; Oligopeptides; Proline; Protease Inhibitors; Sequence Analysis, DNA; Viral Nonstructural Proteins; Young Adult	2013
Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Digestive diseases and sciences, 2013, Volume: 58, Issue:11 Topics: Adult; Aged; Antiviral Agents; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polypharmacy; Proline; Retrospective Studies; Ribavirin; Viral Load	2013
[Therapy of hepatitis C: new inhibitors as hammers against HCV]. MMW Fortschritte der Medizin, 2013, Jun-13, Volume: 155 Suppl 1 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Oligopeptides; Proline; Protease Inhibitors	2013
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. PharmacoEconomics, 2013, Volume: 31, Issue:10 Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Markov Chains; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain	2013
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. Journal of medical economics, 2014, Volume: 17, Issue:1 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin	2014
Treatment of hepatitis C monoinfection in adults--Dutch national guidelines. The Netherlands journal of medicine, 2013, Volume: 71, Issue:7 Topics: Adult; Antiviral Agents; Drug Interactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin	2013
New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2013, Volume: 72, Issue:9 Suppl 4 Topics: Antiviral Agents; Community Health Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Retrospective Studies; Ribavirin; Viral Load	2013
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1 Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Decision Making; Disease Progression; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Time Factors; Watchful Waiting	2014
The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:11-12 Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors	2013
Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role? Pharmacology, 2013, Volume: 92, Issue:5-6 Topics: Adult; Antiviral Agents; Carrier Proteins; Drug Interactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Seizures; Viral Nonstructural Proteins	2013
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1 Topics: Antiviral Agents; Cohort Studies; Comparative Effectiveness Research; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Thrombocytopenia; United States; Veterans	2014
Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology, 2014, Volume: 146, Issue:3 Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Genotype; Hepacivirus; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Liver; Liver Neoplasms; Mutation; Oligopeptides; Proline; Protease Inhibitors; Pyrrolidines; Valine; Viral Nonstructural Proteins	2014
The dilemma for patients with chronic hepatitis C: treat now or warehouse? Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1 Topics: Antiviral Agents; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors; Watchful Waiting	2014
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of hepatology, 2014, Volume: 60, Issue:2 Topics: Antiviral Agents; Contraindications; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin	2014
Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients. Przeglad epidemiologiczny, 2013, Volume: 67, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Female; Genetics, Population; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Mutation; Oligopeptides; Prevalence; Proline; Protease Inhibitors; Sequence Analysis	2013
Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:8 Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Treatment Outcome; United States; Veterans	2014
[Boceprevir and telaprevir utilization: evaluation for the treatment of chronic hepatitis C]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014, Jan-01, Volume: 38, Issue:1 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Treatment Outcome	2014
[Boceprevir and telaprevir safety in routine clinical practice]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014, Jan-01, Volume: 38, Issue:1 Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Humans; Male; Middle Aged; Oligopeptides; Proline; Rectal Diseases; Retrospective Studies; Thrombocytopenia	2014
Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors. Journal of enzyme inhibition and medicinal chemistry, 2014, Volume: 29, Issue:6 Topics: Antiviral Agents; Carbamates; Cloning, Molecular; Cyclopropanes; Drug Resistance, Viral; Escherichia coli; Gene Expression; Genetic Variation; Genotype; Hepacivirus; Isoindoles; Lactams; Lactams, Macrocyclic; Macrocyclic Compounds; Mutation; Oligopeptides; Proline; Protease Inhibitors; Protein Structure, Tertiary; Quinolines; Recombinant Proteins; Sulfonamides; Thiazoles; Viral Nonstructural Proteins	2014
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure. Antiviral research, 2014, Volume: 105 Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viral Nonstructural Proteins	2014
Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:8 Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline	2014
Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. Journal of viral hepatitis, 2014, Volume: 21, Issue:9 Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; End Stage Liver Disease; Female; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kidney; Kidney Function Tests; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load	2014
A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants. PloS one, 2014, Volume: 9, Issue:3 Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Macrocyclic Compounds; Models, Statistical; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Quinolines; Replicon; RNA, Viral; Stochastic Processes; Thiazoles; Viral Nonstructural Proteins; Virus Replication	2014
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). Journal of hepatology, 2014, Volume: 61, Issue:1 Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Models, Economic; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome	2014
Hepatitis C treatment & management. Journal of medicine and life, 2014, Mar-15, Volume: 7, Issue:1 Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate	2014
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:10 Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Severity of Illness Index	2014
[Treatment of hepatitis C infection. A revolution should not hide another]. Presse medicale (Paris, France : 1983), 2014, Volume: 43, Issue:4 Pt 1 Topics: Antiviral Agents; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Risk Reduction Behavior	2014
Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens. Journal of clinical gastroenterology, 2015, Volume: 49, Issue:4 Topics: Antiviral Agents; Cohort Studies; Female; Genotype; Health Personnel; Hematologic Diseases; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Treatment Outcome; Veterans; Viral Load	2015
The position of the Sociedad Española de Patología Digestiva on the current situation of hepatitis C management in Spain. Revista espanola de enfermedades digestivas, 2014, Volume: 106, Issue:1 Topics: Antiviral Agents; Hepatitis C; Humans; Oligopeptides; Proline; Spain	2014
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:5 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Quality-Adjusted Life Years; Sofosbuvir; Uridine Monophosphate	2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology, 2014, Volume: 147, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome	2014
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. AIDS patient care and STDs, 2014, Volume: 28, Issue:5 Topics: Adult; Antiviral Agents; Austria; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult	2014
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. Journal of hepatology, 2014, Volume: 61, Issue:3 Topics: Adult; Aged; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; United States	2014
Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:11 Topics: Antiviral Agents; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin	2014
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS pathogens, 2014, Volume: 10, Issue:5 Topics: Antibodies, Neutralizing; Antiviral Agents; Carbamates; Cell Communication; Cells, Cultured; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Oligopeptides; Proline; Pyrrolidines; Valine; Viral Load; Virus Internalization	2014
A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:6 Topics: Anemia; Antiviral Agents; Biomarkers; Comparative Effectiveness Research; Delivery of Health Care; Drug Prescriptions; Drug Therapy, Combination; Education, Medical, Continuing; Education, Pharmacy, Continuing; Guideline Adherence; Hematinics; Hepacivirus; Hepatitis C; Humans; Medication Therapy Management; Oligopeptides; Pharmaceutical Services; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proline; Registries; RNA, Viral; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Viral Load	2014
Activation of inflammasomes by agents causing idiosyncratic skin reactions: a possible biomarker. Chemical research in toxicology, 2014, Jun-16, Volume: 27, Issue:6 Topics: Biomarkers; Cell Line; Dimethyl Fumarate; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Ethacrynic Acid; Fumarates; Humans; Inflammasomes; Molecular Structure; Oligopeptides; Proline; Skin; Structure-Activity Relationship	2014
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC gastroenterology, 2014, May-05, Volume: 14 Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome; Viral Load	2014
Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors. Virology, 2014, Volume: 456-457 Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Cell Line; Cyclopropanes; DNA Mutational Analysis; GB virus C; Host-Pathogen Interactions; Humans; Interferon Type I; Isoindoles; Lactams; Lactams, Macrocyclic; Mutant Proteins; Oligopeptides; Proline; Protease Inhibitors; RNA Helicases; Serine Endopeptidases; Sulfonamides; Viral Nonstructural Proteins	2014
[Treatment of hepatitis C: current status and perspectives]. La Revue du praticien, 2014, Volume: 64, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome	2014
Cutaneous side-effects of antihepatitis C treatment: the U.K. experience. The British journal of dermatology, 2015, Volume: 172, Issue:1 Topics: Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; United Kingdom	2015
A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nature chemical biology, 2014, Volume: 10, Issue:8 Topics: Animals; Boronic Acids; Carbamates; Carboxylic Ester Hydrolases; Dipeptidyl-Peptidase IV Inhibitors; Drug Discovery; Enzyme Inhibitors; Female; Glucose Tolerance Test; Glutamates; High-Throughput Screening Assays; Humans; Lipopolysaccharides; Macaca fascicularis; Male; Mice, Inbred C57BL; Nitriles; Oligopeptides; Piperazines; Proline; Serine Proteases; Serine Proteinase Inhibitors	2014
A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:9 Topics: Aged; Antiviral Agents; Cyclopropanes; Hepacivirus; Hepatitis C; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Oligopeptides; Proline; Sulfonamides; Treatment Failure	2014
Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. Journal of viral hepatitis, 2015, Volume: 22, Issue:2 Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Middle Aged; Oligopeptides; Proline; Prospective Studies	2015
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. Journal of medical virology, 2014, Volume: 86, Issue:11 Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Plasma; Proline; Ribavirin; Treatment Failure; Viral Load; Viral Nonstructural Proteins; Young Adult	2014
Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. Antiviral research, 2014, Volume: 110 Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Evolution, Molecular; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Sequence Analysis, RNA; Viral Nonstructural Proteins	2014
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:6 Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Digestive diseases and sciences, 2014, Volume: 59, Issue:12 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Young Adult	2014
Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands. Applied health economics and health policy, 2014, Volume: 12, Issue:6 Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Severity of Illness Index	2014
[Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment]. Enfermedades infecciosas y microbiologia clinica, 2015, Volume: 33, Issue:5 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors	2015
Effectiveness research in the evolving HCV landscape. Digestive diseases and sciences, 2014, Volume: 59, Issue:12 Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Proline	2014
Not so sweet: autoimmune diabetes mellitus on triple therapy for chronic hepatitis C infection. Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:2 Topics: Adult; Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Young Adult	2015
"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis. BMC infectious diseases, 2014, Sep-18, Volume: 14 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors	2014
Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. Public health genomics, 2014, Volume: 17, Issue:5-6 Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome	2014
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. PloS one, 2014, Volume: 9, Issue:10 Topics: Decision Making; Drug Therapy, Combination; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Italy; Male; Middle Aged; Oligopeptides; Precision Medicine; Proline; Treatment Outcome	2014
Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:5 Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin	2015
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS (London, England), 2015, Jan-02, Volume: 29, Issue:1 Topics: Adult; Antiviral Agents; Coinfection; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load	2015
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PloS one, 2014, Volume: 9, Issue:11 Topics: Anti-Retroviral Agents; Clinical Laboratory Techniques; Europe; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Oligopeptides; Predictive Value of Tests; Proline; Protease Inhibitors; Reproducibility of Results; RNA, Viral; Treatment Outcome; Viremia	2014
Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PloS one, 2014, Volume: 9, Issue:11 Topics: Antiviral Agents; Drug Monitoring; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Proline; Recombinant Proteins; Ribavirin; Signal Transduction; Treatment Outcome	2014
Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. Journal of viral hepatitis, 2015, Volume: 22, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States; Veterans	2015
Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy. Journal of primary care & community health, 2015, Volume: 6, Issue:3 Topics: Antiviral Agents; Health Services Accessibility; Hepatitis C; Humans; Oligopeptides; Practice Patterns, Physicians'; Primary Health Care; Proline; Rural Health; Rural Health Services; Wisconsin	2015
Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:2 Topics: Aged; Antiviral Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Veterans	2015
Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. Journal of viral hepatitis, 2015, Volume: 22, Issue:9 Topics: Aged; Anemia; Antiviral Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Oligopeptides; Proline; RNA, Viral; Thrombocytopenia; Treatment Outcome; Viral Load	2015
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. Journal of clinical pharmacology, 2015, Volume: 55, Issue:5 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin	2015
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:2 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prognosis; Proline; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load	2015
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study. Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA; Viral Load	2015
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:9 Topics: Anemia; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; France; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Outcome	2015
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation, 2015, Volume: 99, Issue:8 Topics: Antiviral Agents; Biomarkers; Cholestasis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oligopeptides; Proline; Recurrence; Retrospective Studies; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load	2015
Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 65 Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Mutation; Oligopeptides; Polymerase Chain Reaction; Polymorphism, Genetic; Prevalence; Proline; Scotland; Sequence Analysis, DNA; Simeprevir; Viral Nonstructural Proteins	2015
Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:4 Topics: Antiviral Agents; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Practice Patterns, Physicians'; Proline; Retrospective Studies; United States	2015
Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Digestive diseases and sciences, 2015, Volume: 60, Issue:4 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult	2015
First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virology journal, 2015, Mar-03, Volume: 12 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies	2015
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. PloS one, 2015, Volume: 10, Issue:4 Topics: Adult; Coinfection; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome	2015
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. Journal of clinical microbiology, 2015, Volume: 53, Issue:7 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins	2015
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. Journal of viral hepatitis, 2015, Volume: 22, Issue:12 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Tertiary Care Centers; Treatment Outcome; Viral Load	2015
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 68 Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Incidence; Male; Membrane Transport Proteins; Middle Aged; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Pyrophosphatases; Ribavirin; Risk Assessment; Young Adult	2015
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients. Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:1 Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythrocyte Indices; Erythrocyte Membrane; Erythropoiesis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin; Treatment Outcome	2016
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clinical therapeutics, 2015, Volume: 37, Issue:8 Topics: Adult; Aged; Anemia; Antiviral Agents; Databases, Factual; Drug Costs; Drug Eruptions; Drug Therapy, Combination; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; United States	2015
THE ABSENCE OF THYROID DISEASE IN AN AUSTRALIAN HEPATITIS C COHORT TREATED WITH TRIPLE COMBINATION THERAPY: A PARADIGM SHIFT. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015, Volume: 21, Issue:9 Topics: Adult; Australia; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Thyroid Diseases	2015
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs. Journal of medical virology, 2016, Volume: 88, Issue:1 Topics: Adult; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome	2016
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV medicine, 2015, Volume: 16, Issue:10 Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; HIV Infections; Humans; Leucine; Male; Middle Aged; Oligopeptides; Patient Acceptance of Health Care; Proline; Prospective Studies; Protease Inhibitors; Quinolines; RNA, Viral; Switzerland; Thiazoles; Viral Load	2015
Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? Journal of clinical gastroenterology, 2016, Volume: 50, Issue:3 Topics: Aged; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Ribavirin; Surveys and Questionnaires; White People	2016
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. Journal of viral hepatitis, 2015, Volume: 22, Issue:12 Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Random Allocation; Ribavirin; Treatment Outcome; Viral Load	2015
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:10 Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides	2015
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. Journal of pharmaceutical and biomedical analysis, 2015, Nov-10, Volume: 115 Topics: Antiviral Agents; Automation, Laboratory; Chromatography, Liquid; Drug Monitoring; Hepatitis C; Humans; Isomerism; Leukocytes, Mononuclear; Limit of Detection; Linear Models; Oligopeptides; Proline; Reference Standards; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry; Time Factors	2015
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients. The Netherlands journal of medicine, 2015, Volume: 73, Issue:7 Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sustained Virologic Response	2015
[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice]. Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:10 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hematologic Diseases; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Remission Induction; Retrospective Studies; Ribavirin; Spain	2015
Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. The International journal on drug policy, 2015, Volume: 26, Issue:10 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Opiate Substitution Treatment; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome	2015
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy. Antiviral therapy, 2016, Volume: 21, Issue:2 Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin	2016
Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future? PloS one, 2015, Volume: 10, Issue:9 Topics: Adult; Aged; Anemia; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Postoperative Period; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Recurrence; Thrombocytopenia; Treatment Outcome	2015
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role? European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:1 Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load	2016
Development and persistence of DAA resistance associated mutations in patients failing HCV treatment. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 72 Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Mutation, Missense; Oligopeptides; Proline; Sequence Analysis, DNA; Treatment Failure; Viral Nonstructural Proteins	2015
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Adenine; Alanine; Anti-HIV Agents; Biotransformation; Carboxylic Ester Hydrolases; Cathepsin A; CD4-Positive T-Lymphocytes; Cobicistat; Drug Interactions; Gene Expression; HEK293 Cells; HeLa Cells; HIV-1; Host-Pathogen Interactions; Humans; Oligopeptides; Primary Cell Culture; Prodrugs; Proline; RNA, Small Interfering; Serine Proteinase Inhibitors; Tenofovir	2016
Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. Expert opinion on drug safety, 2015, Volume: 14, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Young Adult	2015
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 73 Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Viral Load	2015
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PloS one, 2015, Volume: 10, Issue:12 Topics: Anemia; beta 2-Glycoprotein I; Drug Therapy, Combination; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Pyrophosphatases; Treatment Outcome	2015
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. Journal of viral hepatitis, 2016, Volume: 23, Issue:5 Topics: Adult; Aged; Antiviral Agents; Biopsy; Female; Gene Expression Profiling; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Liver; Macrophages; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Staining and Labeling	2016
Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity. PloS one, 2016, Volume: 11, Issue:3 Topics: Animals; Computer Systems; Disease Models, Animal; Hepacivirus; Liver; Luciferases; Mice, Transgenic; Oligopeptides; Plasmids; Proline; Protease Inhibitors; Reproducibility of Results; Viral Nonstructural Proteins	2016
Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2016, Volume: 78 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Treatment Failure; Viral Load	2016
[Resistance to protease inhibitors and efficiency of antiviral therapy in patients with chronic hepatitis C]. Terapevticheskii arkhiv, 2016, Volume: 88, Issue:3 Topics: Adult; Aged; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Simeprevir; Young Adult	2016
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy. AIDS (London, England), 2016, 08-24, Volume: 30, Issue:13 Topics: Anemia; Antiviral Agents; Coinfection; Decision Support Techniques; Drug Therapy, Combination; Female; Genotyping Techniques; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Male; Membrane Transport Proteins; Oligopeptides; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Proline; Ribavirin	2016
Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. PloS one, 2016, Volume: 11, Issue:5 Topics: Algorithms; Antiviral Agents; Cell Line; Drug Resistance, Viral; Genetic Association Studies; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Internet; Mutation; Oligopeptides; Phenotype; Proline; Simeprevir; Software	2016
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016, Jun-23, Volume: 49, Issue:7 Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Sustained Virologic Response; Time Factors; Treatment Failure; Young Adult	2016
Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2016, Volume: 50 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Oligopeptides; Proline; Protease Inhibitors; Simeprevir; Turkey; Viral Nonstructural Proteins; Young Adult	2016
[FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA]. Harefuah, 2016, Volume: 155, Issue:5 Topics: Adult; Antiviral Agents; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Israel; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome	2016
Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients. International journal of molecular sciences, 2016, 08-27, Volume: 17, Issue:9 Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; High-Throughput Nucleotide Sequencing; Humans; Mutation; Oligopeptides; Proline; Simeprevir; Viral Nonstructural Proteins	2016
The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors. PloS one, 2016, Volume: 11, Issue:10 Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C Antigens; Humans; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors	2016
The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data. European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:5 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Germany; Hepatitis C, Chronic; Humans; Incidence; Insurance, Health; Male; Middle Aged; Oligopeptides; Prevalence; Proline; Retrospective Studies	2017
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study. Journal of viral hepatitis, 2017, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; British Columbia; Cohort Studies; Female; Healthcare Disparities; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Young Adult	2017
Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. BMC health services research, 2017, 04-19, Volume: 17, Issue:1 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ireland; Male; Middle Aged; Oligopeptides; Proline; Propensity Score; Prospective Studies; Registries; Ribavirin; Treatment Outcome; Uncertainty	2017
The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:1 Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Risk Factors; Sofosbuvir	2017
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2017, Volume: 53 Topics: Amino Acid Substitution; Antiviral Agents; Bayes Theorem; Carrier Proteins; Cohort Studies; Databases, Genetic; Drug Resistance, Viral; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Protease Inhibitors; RNA, Viral; Viral Nonstructural Proteins	2017
Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort. Medical microbiology and immunology, 2017, Volume: 206, Issue:5 Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Drug Monitoring; Female; Fluorescent Antibody Technique, Indirect; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Treatment Outcome	2017
Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. Journal of immunology (Baltimore, Md. : 1950), 2018, 02-01, Volume: 200, Issue:3 Topics: Adaptive Immunity; Antibodies, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Immunologic Memory; Interferon-alpha; Longitudinal Studies; Lymphocyte Activation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; T-Box Domain Proteins; Treatment Outcome	2018
The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Upsala journal of medical sciences, 2018, Volume: 123, Issue:1 Topics: Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Middle Aged; Mutation; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Viral Nonstructural Proteins	2018
Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. Value in health regional issues, 2019, Volume: 20 Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Oligopeptides; Proline; Public Health Practice; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome	2019
Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos de saude publica, 2020, Volume: 36, Issue:2 Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin	2020
Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. Journal of hepatology, 2021, Volume: 74, Issue:1 Topics: Antiviral Agents; Cause of Death; Disease Progression; Female; France; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Mortality; Oligopeptides; Proline; Substance-Related Disorders; Sustained Virologic Response	2021
SARS-CoV-2 M Science (New York, N.Y.), 2021, 03-26, Volume: 371, Issue:6536 Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Chemokine CXCL10; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Drug Design; Humans; Interferon-beta; Lung; Mice; Mice, Transgenic; Oligopeptides; Proline; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Viral Load; Virus Replication	2021
Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation. Biochemical and biophysical research communications, 2021, 05-28, Volume: 555 Topics: Adaptation, Physiological; Amino Acid Sequence; Antiviral Agents; Binding Sites; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Design; Drug Resistance, Viral; Genetic Fitness; Hepacivirus; Ligands; Models, Molecular; Mutation; Oligopeptides; Proline; Reproducibility of Results; SARS-CoV-2; Selection, Genetic; Structure-Activity Relationship	2021